METHOD FOR TREATING SYSTEMIC DNA MUTATION DISEASE

Abstract

The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a Divisional of U.S. application Ser. No. 14/309,363, filed Jun. 19, 2014, which is a Continuation of U.S. application Ser. No. 13/772,499 filed Feb. 21, 2013, now U.S. Pat. No. 8,796,004, which is a Continuation of U.S. application Ser. No. 12/835,029 filed Jul. 13, 2010, now U.S. Pat. No. 8,388,951, which is a Continuation-in-Part of U.S. application Ser. No. 10/564,609 filed Jan. 12, 2006, which is a U.S. national phase application under 35 U.S.C. .sctn.371 of International Patent Application No. PCT/RU2004/000260, filed Jul. 1, 2004 (published in Russian on Jan. 20, 2005 as WO 2005/004789), which claims priority of Russian Federation Patent Application No. RU2004108057, filed Mar. 12, 2004 and International Patent Application No. PCT/RU2003/000304 filed Jul. 14, 2003, all of which applications are incorporated by reference herein in their entirety.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 16, 2014, is named 243736.000083_SL.txt and is 59,899 bytes in size.

BACKGROUND OF THE INVENTION

[0003] 1. Field of the Invention

[0004] The present invention relates generally to medical treatment of the systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis.

[0005] 2. Description of the Related Art

[0006] Mosaicism refers to a mixture of cells of different genetic composition in one individual. When DNA mutation is detectable in number, but not all somatic cells in one individual, it is called somatic mosaicism. Development of somatic mosaicism has been recently recognized as important mechanism of systemic DNA mutation diseases progression (Gottlieb B et al., Selection and mutation in the "new" genetics: an emerging hypothesis, Hum Genet. 2010 March; 127(5): 491-501.) Importance of somatic mosaicism involving disease-causing mutations has been reported for variety of monogenic (reviewed by Youssoufian H., Nature Reviews Genetics 3, 748-758, October 2002) and more recently for multifactor DNA mutation diseases: cardiac rhythm disorders (M. H. Gollob et al., Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation, N. Eng. J. Med. 354 (2006), pp. 2677-2688.); atherosclerosis (S. De Flora et al., Mutagenesis and cardiovascular diseases. Molecular mechanisms, risk factors, and protective factors, Mutat. Res. 621 (2007), pp. 5-17), systemic vascular disorders (B. Gottlieb et al., BAK1 gene variation and abdominal aortic aneurysms, Hum. Mutat. 30 (2009), pp. 1043-1047); immune deficiencies (Wada T. et al., Somatic mosaicism in primary immune deficiencies, Curr Opin Allergy Clin Immunol. 2008 December; 8(6): 510-4); Alzheimer disease (Beck J A et al., Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Hum Mol Genet. 2004 Jun. 15; 13(12): 1219-24.); diabetes mellitus (Emma L. Edghill et al, Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 5 1773-1777).

[0007] According to current knowledge the systemic DNA mutation diseases represent very distinct subsets of human pathology different in etiology and pathogenesis and accordingly has fundamentally different, usually palliative treatment modalities-cholesterol lowering therapy for atherosclerosis (New Concepts and Paradigms in Cardiovascular Medicine: The Noninvasive Management of Coronary Artery Disease, K. Lance Gould, THE AMERICAN JOURNAL OF MEDICINE, Volume 104, Jun. 22, 1998, pp. 2-17) and insulin therapy or insulin sensitization therapy for diabetes mellitus (Pharmacological Management of Diabetes: Recent Progress and Future Perspective in Daily Drug Treatment, Gerard Emilien et al., Pharmacol. Ther. Vol. 81, No. 1, pp. 37-51, 1999).

[0008] More recently the gene therapy was recognized as potential tool for disease specific intervention which may target the function of certain specific disease involved genes and provide more efficient cure based on repair of existing genetic defects in atherosclerosis (Ishisaki A, et al., Novel ideas of gene therapy for atherosclerosis: modulation of cellular signal transduction of TGF-beta family. Curr Pharm Des. 2006; 12(7): 877-86; Harris J D, et al. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther. 2006 August; 8(4): 275-87; Hayden et al. Gene therapy method for reducing risk of atherosclerosis, U.S. Pat. No. 6,784,162) and diabetes mellitus (G B Parsons, Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes, Gene Therapy (2007) 14, 38-48; L. Chan, In vivo gene therapy for diabetes mellitus, Trends in Molecular Medicine, Volume 9, Issue 10, October 2003, Pages 430-435; M. During, Compositions for gene therapy of diabetes, EP1889914).

[0009] However no cure exists which may target the evolution of disease causing DNA mutations leading to development of somatic mosaicism. Accordingly, the development of new effective, non-toxic method that may suppress the development of somatic mosaicism and consequently be effective cure for systemic DNA mutation disease is an extremely important task.

[0010] Circulating extracellular nucleic acids were discovered more than 60 years ago (Anker P Circulating DNA in plasma or serum, Clin Chim Acta. 2001 November; 313(1-2): 143-6). However until now elevated levels of extracellular blood DNA in systemic DNA mutation diseases, and in particular in atherosclerosis and diabetes mellitus were considered only as useful diagnostic and research tool (El Tarhouny S. A. et al., Assessment of cell-free DNA with microvascular complication of type II diabetes mellitus, using PCR and ELISA. Nucleosides Nucleotides Nucleic Acids. 2010 March; 29(3): 228-36; Langford M P et al., Plasma levels of cell-free apoptotic DNA ladders and gamma-glutamyltranspeptidase (GGT) in diabetic children. Exp Biol Med (Maywood). 2007 October; 232(9): 1160-9; Arnalich F. et al., Prognostic value of cell-free plasma DNA in patients with cardiac arrest outside the hospital: an observational cohort study, Critical Care 2010, 14; Arnalich F. Association of cell-free plasma DNA with preoperative mortality in patients with suspected acute mesenteric ischemia, Clinica Chimica Acta, in press; Zhong S, Presence of mitochondrial tRNA (Leu (UUR)) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus 2000 June; 53(6): 466-9.)

[0011] Circulating extracellular nucleic acids have never been considered as potential therapeutic target in systemic DNA mutation diseases. Accordingly, no therapeutic method was developed which targets extracellular blood DNA in systemic DNA mutation diseases. Thus it makes impossible to take any technical solution as prototype.

[0012] As used in this application, the following terms are meant to have the following corresponding definitions.

[0013] Deoxyribonuclease (DNASE) is any enzyme that catalyzes the hydrolytic cleavage of phosphodiester linkages in the DNA backbone.

[0014] Extracellular blood DNA number average molecular weight--the number average molecular weight is a way of determining the molecular weight of a polymer. The number average molecular weight is the ordinary arithmetic mean or average of the molecular weights of the individual DNA macromolecules. It is determined by measuring the molecular weight of n polymer molecules, summing the weights, and dividing by n. The number average molecular weight of extracellular blood DNA can be determined by gel electrophoresis. The shift of extracellular blood DNA bands to low-MW areas reflect decrease number average molecular weight and in fact reflects enzymatic cleavage of extracellular blood DNA.

[0015] DNA mutation disease refers to diseases where specific DNA mutation has been identified as single leading cause (monogenic or single gene disorders) or multifactor disorders resulting from mutations in multiple genes, often coupled with environmental causes.

[0016] Systemic disease is one that affects a number of organs and tissues, or affects the body as a whole.

SUMMARY OF THE INVENTION

[0017] The object of this invention is to develop high-performance and low-toxic method for treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis.

[0018] According to the invention this task is resolved by introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic DNA mutation disease when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme. In one of preferred embodiments said agent must be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. In one of preferred embodiments the method according the invention can be effectively applied for treatment of diabetes mellitus and atherosclerosis. A DNASE enzyme may be further applied in a dose and regime that results in a DNA hydrolytic activity measured in blood plasma that exceeding 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.

[0019] The present invention suggests that systemic DNA mutation disease can be treated by reducing of circulating extracellular blood DNA levels.

[0020] Development of systemic DNA mutation disease in humans is accompanied by quantitative and/or qualitative change of blood extracellular DNA.

[0021] There are no analysis of blood extracellular DNA spectrum and its biological role in systemic DNA mutation disease prior to this invention. A search of the prior art reveals no published data concerning an analysis of blood extracellular DNA spectrum in systemic DNA mutation disease performed by direct cloning and without use of polymerase chain reaction (PCR). PCR can pervert a pattern of blood extracellular DNA because of specificity of primers used for amplification. There is no available knowledge about genetic repertoire of extracellular blood DNA in patients suffering from systemic DNA mutation disease and about biological role of extracellular blood DNA in course of these diseases. Nothing is known about potential therapeutic value of extracellular blood DNA enzymatic destruction for treatment of systemic DNA mutation disease; so, taking into account all aforesaid, the invention complies with requirements of "novelty" criteria (N).

[0022] As the applicant established by direct cloning and sequencing of extracellular blood DNA without PCR (Polymerase Chain Reaction), the extracellular blood DNA of patients with systemic DNA mutation disease contains the unique quantitative and qualitative repertoire of genes, which non-randomly represents human genome and contains genetic elements involved in to the development of the disease. It was shown that extracellular blood DNA might promote the development of somatic mosaicism and systemic DNA mutation disease.

[0023] It was established that enzymatic destruction of extracellular blood DNA by DNASE enzyme when applied in certain surprisingly high specific doses has significant therapeutic effect on the course of systemic DNA mutation disease.

[0024] Aforesaid new characteristics of the claimed invention are based on new ideas about mechanism of development of systemic DNA mutation disease. In this way the claimed method conformances to requirements of "invention step" criteria (IS).

BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The advantages and features of the present invention have been explained by detailed description of embodiments with references to drawings:

[0026] FIG. 1: NF-kappa B expression in (A) cultured aortic endothelial cells treated with extracellular blood DNA fraction from patient suffering from systemic atherosclerosis; (B) cultured aortic endothelial cells treated with extracellular blood DNA fraction from patient suffering from systemic atherosclerosis plus 1 mkg/ml of DNASE1; and (C) control cells.

[0027] FIG. 2A-2B: FIG. 2A shows a graph of the survival of NOD diabetic mice treated with different doses of DNASE1--50 mkg/kg, 500 mkg/kg, and control; FIG. 2B shows average molecular weight of extracellular blood plasma DNA (as measured by electrophoresis) in blood of NOD diabetic mice treated with 50 mkg/kg DNASE 1 (A), 500 mkg/kg DNASE1 (B), and control (C).

[0028] FIG. 3A-3B: Results of immunochemical staining of mice tumor's histological slices after administration of 5 day course of Doxorubicin therapy (2 mg/kg every day intravenous) and DNase 1 (0.5 mg/kg four times a day during 5 days). 3A--Doxorubicin+DNase; 3B--Doxorubicin.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The inventive method is realized as follows:

[0030] Materials and Methods:

[0031] The following agents, which destroy extracellular blood DNA, were used: bovine pancreatic DNASE (Sigma, specific activity 2 400 Kunitz units/mg; Samson-Med, specific activity 1 500 Kunitz units/mg), recombinant human DNASE 1 (Gentech, specific activity 1000 U/mg).

[0032] Extracellular DNA from blood plasma was isolated as follows: fresh plasma (no more than 3-4 hours after sampling) with anticoagulant (sodium citrate) was centrifuged on Ficoll-Plaque Plus (Amersham-Pharmacia) during 20 minutes at 1500 g. at room temperature. 1/2 of plasma was detached, not affecting the rest of cells on the Ficoll pillow, and further centrifuged at 10000 g. during 30 min for separation from cell fragments and debris. Supernatant was detached, without affecting of the sediment, and was toped up to 1% of sarkosil, 50 MM tris-HCl, pH 7.6, 20 MM EDTA, 400 MM NaCl, and then mixed with equal volume of phenol-chloroform(1:1) mixture. The prepared emulsion was incubated during 2 hours at t=65.degree. C., then phenol-chloroform mixture was separated by centrifuging (500 g during 20 minutes, room temperature). The procedure of deproteinization with phenol-chlorophorm mixture was repeated 3 times, and then the water phase was processed with chloroform and diethyl ether. Separation from organic solvents was made by centrifugation at 5000 g during 15 minutes. Then equal volume of izopropanol was added to resulting aqueous phase and the mixture was incubated overnight at 0.degree. C. After sedimentation the nucleic acids were separated by centrifugation at 10000 g during 30 minutes. The sediment of nucleic acids was dissolved in of 10 MM tris-HCl buffer, pH 7, 6 with 5 MM EDTA, and inflicted to the CsCl gradient (1M, 2.5M, 5.7M) in test-tube for rotor SW60Ti. The volume of DNA solution was 2 ml, volume of each step of CsCl was 1 ml. Ultracentrifugation was conducted in L80-80 (Beckman) centrifuge during 3 hours at 250000 g. DNA was collected from the surface of each gradient step into fractions. These fractions were dialyzed during 12 hours (t=4.degree. C.) and pooled. Presence of DNA in fractions was determined by agar electrophoresis and DNA was visualized by ethidium bromide staining. The amount of DNA was determined with spectrophotometer (Beckman DU70) in cuvetts (100 mkl) at wavelength of 220-230 nm.

[0033] NOD mice were obtained from <<Pushcino>> animal breeding house.

Example 1

DNASE Treatment Suppresses the Development of Somatic Mosaicism

[0034] Frequency of HPRT gene's mutations in blood T-lymphocytes was studied as the model of development of somatic mosaicism in vivo. The human HPRT gene, mapped to chromosome Xq26, codes for a constitutively expressed, but non-essential, enzyme involved in purine metabolism. Mutant peripheral blood T-lymphocytes which do not express a functional HPRT gene product can be enumerated and clonally expanded by selective growth in the normally toxic purine analog 6-thioguanine in the presence of specific mitogens and growth factors. In normal, unexposed individuals the frequency of 6-thioguanine resistant T-lymphocytes is typically 10.sup.-6 to 10.sup.-5 (R. J. Albertini, J. A. Nicklas, J. P. O'Neill, S. H. Robison, In vivo somatic mutations in humans: measurement and analysis, Annu. Rev. Genet. 24 1990. 305-326.) Molecular analyses of the mutant, HPRT deficient, clones have demonstrated that 85% of the gene inactivating mutations observed in unexposed adults arises by localized HPRT gene alterations--single base changes, small deletions or insertions and frame shift.

[0035] Selective lymphocyte cloning was performed using peripheral blood of 8 female patients with different forms of advanced cancer who got surgical resection at Kostushko municipal Hospital (St. Petersburg) and immunomodulation therapy at neoadjuvant setting (Neovir, 250 mg IM once every 2 days for 3 weeks). Following surgical resection 4 patients were further treated by IV infusions of bovine pancreatic DNASE (Samson) according the following schedule: 2000 mkg/kg.times.4 times daily for 21 day. Following completion of treatment the patients were assayed for HPRT (-) mutation in blood lymphocytes.

[0036] Mononuclear cells were isolated from the whole blood samples using Ficoll-Paquee (Becton Dickinson). Mitogenic stimulation of the separated lymphocytes (1.times.10.sup.6/ml) was initiated with 1 mg/ml phytohemagglutinin (PHA) in RPMI 1640 media supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), 20% nutrient medium HL-1 and 5% BSA at 5% CO.sub.2 at 37.degree. C. for 24 h. Following wash the cells were then seeded in 96-well round-bottomed plates at cell density of 2.times.10.sup.4 cells per well in selection medium to determine cloning efficiency. The cells were plated in 200 ml of the RPMI medium containing 1 mg/ml 6-thioguanine, 0.125 mg/ml PHA, 20% HL-1 and 5% BSA supplemented with interleukin-2 (BD Biosciences, 10 BRMP units/mi). Four 96-well plates were seeded for each patient. After 5 days of culture, the colonies on mutant selection plates were scored for growth using an inverted microscope.

[0037] The results of selective T-lymphocyte cloning are presented in the table below:

TABLE-US-00001 Total number of HPRT wells Patient Treatment wells (growth positive) KNP DNASE 384 7 PGP DNASE 384 12 BAI DNASE 384 2 FVV DNASE 384 11 SLS NO 384 47 GAN NO 384 22 PMI NO 384 31 ENV NO 384 55

[0038] Thus, inventive treatment suppresses spread of HPRT (-) mutation and suppresses the development of somatic mosaicism.

Example 2

Extracellular Blood DNA Promotes the Development of Somatic Mosaicism

[0039] The extracellular blood plasma DNA was purified from blood of patient ENV as specified in methods section. Mononuclear cells were isolated from the whole blood samples of patients KNP, PGP, BAI and FW as specified in Example 1. The mitogenic stimulation and selective cloning were performed as specified in Example 1 with modification as follows: during mitogenic activation stage lymphocyte cultures of patients KNP, PGP, BAI and FW were supplemented with 50 mkg/ml of extracellular blood plasma DNA purified from patient ENV. After 5 days of culture, the colonies on mutant selection plates were scored for growth using an inverted microscope. The results of selective T-lymphocyte cloning are presented in the table below:

TABLE-US-00002 Total number of HPRT wells Patient wells (growth positive) KNP 384 18 PGP 384 15 BAI 384 21 FVV 384 31

[0040] Thus, extracellular blood DNA promotes the development of somatic mosaicism.

Example 3

Sequencing of Extracellular Blood DNA from the Patient Suffering from

[0041] Type 2 Diabetes and Systemic Atherosclerosis. Treatment of Atherosclerosis.

[0042] A 54-year-old man has been admitted to the Cardiothoracic surgery department of Kostushko municipal hospital (St. Petersburg) in severe condition complaining on intensive pain in abdomen, diarrhea, intensive pain in legs that appear during walking, loss of weight. Diabetes mellitus type 2 was diagnosed 12 years ago and glybencamide was prescribed. Pain in epigastrium after food intake appeared 15 months ago. Antacids were prescribed but pain continued to increase and steatorrhea appeared in the last 3 months. Because of intensive pain syndrome anorexia has developed in a couple of days prior admittance. Considerable exhaustion (body weight was 44 kg; body weight loss was 28 kg for the last 5 months) and absence of arterial pulsation on legs were found out during examination. No organic changes were observed during gastroduodenoscopy and colonoscopy. Electrocardiographic data was not changed pathologically. Moderate increase of cholesterol level and low-density lipoprotein fraction was observed in blood analysis. Glycated hemoglobin' level was 11%. Partial occlusion of aorta below renal artery (70%), partial occlusion of iliac arteries (90%), total occlusion of upper and lower mesenteric artery were observed on aortography.

[0043] The probes of patient's extracellular blood DNA were taken before initiation and on day 35 of therapy. The extracellular DNA was cloned by the method which allows to get non amplified plasmid libraries of blood extracellular DNA with representativeness up to one million of clones with the average size of 300-500 base pairs. The DNA which has been isolated using the protocol specified in Materials and Methods section was treated with Proteinase K (Sigma) at 65.degree. C. and subjected to additional phenol-chloroform extraction step with further overnight precipitation by ethanol. The DNA fraction was than treated by Eco RI restrictase or by Pfu polymerase (Stratagene) in presence of 300 mkM of all desoxynucleotidetriphosphates for sticky-ends elimination. The completed DNA was phosphorylated by polynucleotidkinase T4 and ligated to pBluescript plasmid (Stratagene), which had been digested with EcoRI or PvulI and dephosphorylated by phosphatase CIP (Fermentas). The process of ligation was conducted with Rapid Legation Kit (Roche). The ligated library was transformed into DH12S cells (Life Technologies) by electroporation (E. Coli porator; BioRad). 12-20 electroporation covets were used for the transformation of one library. The library serial dilutions were cloned on 1.5% agar and LB media supplemented with ampicillin. In both cases the libraries represented 2-3.times.10.sup.6 clones.

[0044] Analysis of 75 randomly selected clones with the size 300-1000 base pairs from the "before treatment" library revealed 56 clones containing unique human DNA sequences as presented at the table below:

TABLE-US-00003 Potential role in Number of Atherosclerosis/diabetes Gene clones mellitus Neutral endopeptidase 2 At atherosclerosis its activity is increased in endothelial cells, nonstriated muscle cells, stromal cells of artery' intima. Decreasing of its activity can decrease lipids accumulation in vessels wall. Muskelin 1 1 Works as mediator of cell response on thrombospondin 1. Thrombospondin 1 - mediated processes are pathophysiological components of atherosclerotic affection of artery wall. Nf-kappaB 3 At hyperglycemia and atherosclerosis activity is increased in cells of artery wall. E-selectin 3 High level of expression is a risk factor of angiopathy development at diabetes type 2. GAD2: glutamate 2 2 One of the main pancreatic decarboxylase 2 autoantigens. Phospholipase C, epsilon 2 Induces expression of receptors of low-density lipoproteins BAI3: brain-specific 1 Angiogenesis inhibitor angiogenesis inhibitor Nicotinamide nucleotide 1 Involved in detoxification transhydrogenase of reactive oxygen species and insulin secretion. 17 kD fetal brain protein 1 UNCLEAR CRTL1: cartilage linking 1 Involved in morphogenetic protein 1 process in heart and large vessels Transient receptor potential 1 UNCLEAR cation channel

[0045] Thus, extracellular blood DNA from patient having diabetes mellitus and systemic atherosclerosis contains significant non-random presence of human disease-relevant unique genomic DNA.

[0046] Patient was considered as not eligible for surgery so, conservative therapy was chosen. Intensive IV nutrition was started. Insulin and anti-aggregation therapy have being started. Under patient consent daily intravenous infusions of bovine pancreatic DNASE (Samson) at daily dose of 800 mg (1 200 000 Kuntz units) divided to 4 two-hour deliveries were started. Week after start of DNASE therapy pain syndrome disappeared and patient was allowed to take light dietetic food orally. 20 days after start of DNASE treatment patient was switched to full value oral nutrition. General state was improved, body weight has increased. 45 days following initiation of DNASE treatment patient was reexamined by angiography. 20% decrease of aorta occlusion and 35% decrease of iliac artery occlusion level as well as appearance of blood circulation in upper and lower mesenteric was observed. Patient was considered as eligible for revascularization surgery.

[0047] Extracellular blood plasma DNA sampled from patients blood at day 35 following start of DNASE therapy was assayed by gel electrophoresis and cloning. Analysis of 50 clones randomly chosen from the library obtained from the extracellular blood plasma DNA of patient on the day 35 after the beginning of treatment has shown that more than 90% of revealed clone sequences are short fragments of repetitive human DNA with the dominance of alpha-satellite DNA.

Example 4

Influence of Extracellular Blood DNA from the Patient with Systemic Atherosclerosis on Disease Causing Protein Expression in Aortic Endothelial Cells

[0048] Endothelial NF-kappa B signaling orchestrates proinflammatory gene expression at the arterial wall and promotes the pathogenesis of atherosclerosis. Here we assayed the influence of extracellular blood DNA from the patient diagnosed with systemic atherosclerosis on NF kappa B expression in primary aorta endothelial cell culture. Blood plasma was obtained from vascular surgery clinic of St. Petersburg Medical Academy from the patient undergoing femoro-femoral bypass surgery due to severe atherosclerotic arterial occlusion.

[0049] The extracellular blood DNA was purified as described in Materials and Methods section. The aortic endothelial cells (C-006-5C; Invitogen) were plated at density of 5-8.times.10.sup.2 cells/mm.sup.2 in multiwell (12.times.) cell culture plates in Clonetics.RTM. EGM.RTM.-2MV media (Lonza Cologne AG) and incubated for 48 h. at 37.degree. C. and 5% CO.sub.2. Following 24 h of growth the culture media was supplemented with 50 mkg/ml of patient extracellular blood DNA fraction or 50 mkg/ml of patient extracellular blood DNA fraction plus human recombinant DNASE-1 (Genentech) at 1 mkg/ml concentration.

[0050] After 24 h. culturing the explants were lysed in buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM phenylmethylsulfonylfluoride, 5 mg/ml aprotinin, 0.5% Nonidet P-40 (Sigma-Aldrich) for 1 hour at 4.degree. C. The lysates were centrifuged for 10 min at 20,000 rpm. The supernatants were diluted with reducing sample buffer and were separated by electrophoresis on a 10% SDS-PAGE gel (20 mkg protein per lane loaded). The proteins were transferred onto Hybond-C-nitrocellulose membrane (Amersham Italia, Milan, Italy. For immunoblot analysis, the membranes were incubated with the NF-.kappa.B antibodies (Stressgen). The bands were detected using the chemiluminescence system.

[0051] The results are presented at the FIG. 1. Extracellular blood DNA fraction from patient suffering from systemic atherosclerosis increases the expression of NF-kappa B in cultured aortic endothelial cells and treatment with DNASE ameliorate this effect.

Example 5

Treatment of Diabetes Mellitus

[0052] Non-obese diabetic (NOD) mice exhibit a susceptibility to spontaneous development of autoimmune insulin dependent diabetes mellitus. 60 NOD mice were recruited to the study at the age of 14 weeks when all of them became hyperglycemic. The recombinant human DNASE 1 (Gentech) at 50 mkg/kg and 500 mkg/kg was administered intramuscularly twice daily for 21 day. 2 mice from each group were sacrificed at the last treatment day to perform evaluation of extracellular blood plasma DNA. The efficacies of DNASE were assessed based on the survival rate at day 35. The results of experiments are presented at the FIG. 2. There is evident increase in survival of mice treated with 500 mkg/kg DNASE 1; such survival is accompanied with decrease of average molecular weight of extracellular blood plasma DNA (as measured by electrophoresis) in blood of NOD diabetic mice. Thus, high doses of DNASE according to inventive treatment are able to decrease the quantities of circulating extracellular blood plasma DNA and are effective against systemic DNA mutation disease-diabetes mellitus.

Example 6

Treatment of Diabetes Mellitus

[0053] A 46-years-old patient with 3 years history of type 2 diabetes mellitus was admitted to the internal therapy clinic of St. Petersburg Medical Academy. Patient failed to achieve proper glucose control using oral hypoglycemic agents including those of thiazolidinediones, biguanides and sulfonylureas. Patient was switched to 0.3 IU/kg of NPH insulin monotherapy (21 IU daily) and discharged from clinics under the supervision of ambulatory endocrinologist. Three month later patient was readmitted to the clinic since glycosylated hemoglobin (HbA1) level was still too high (above 10%) with evolving microalbuminuria and decrease in vision sharpness despite daily insulin dose was adjusted up to 1.2 U/kg (84 U/day) during ambulatory period. Under patient consent he was assigned for intramuscular injections of bovine pancreatic DNASE (Samson) twice daily at 200 mg/day dose for 4 months and again discharged from clinics. At 4 month after initiation of treatment patient were reexamined in clinics outpatient department. Significant improvement in insulin sensitivity, improvement of glycemia control and normalization of kidney function has been reported by patient ambulatory endocrinologist and confirmed by laboratory examination in clinic. The effect of DNASE treatment on patient disease indicators is presented in table below:

TABLE-US-00004 Prior At DNASE DNASE course Indicator treatment completion Insulin requirement 1.2 IU/kg 0.6 IU/kg HbA1 13.2% 7.2% 24 h. albuminuria 275 mg 60 mg

Thus, the inventive treatment is effective in diabetes mellitus.

Example 7

[0054] Atherosclerosis is a systemic disease that is accompanied by formation of specific atherosclerotic plaques in large and middle sized artery walls. Depends on the localization, stage and size of atherosclerotic plaques the disease has different clinical signs (angina, stroke and so on). The signs especially associated with organ dysfunction caused by systemic atherosclerosis are cured by drug therapy or by surgical operation. There is no cure for Atherosclerosis by drug therapy methods as for any systemic disease. An established method of prevention that delays the disease progression is therapy with inhibitors of 3 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase (Lovastatin, Parvastatine e.t.c.) leading to the inhibition of endogenous cholesterol synthesis and increasing of clearance of low density lipoproteins of blood plasma and it attenuates atherosclerosis development (New Concepts and Paradigms in Cardiovascular Medicine: The Noninvasive Management of Coronary Artery Disease, K. Lance Gould, THE AMERICAN JOURNAL OF MEDICINE, Volume 104, Jun. 22, 1998, 2s-17s). Disadvantages of such treatment are adverse effects (A safety look at currently available statins, Moghadasian M H, Expert Opin Drug Saf 2002 September 1 pp. 269-74) and limited efficacy (Statins: balancing benefits, efficacy and safety, Clearfield M B, Expert Opin Pharmacother, 2002, May 3 pp. 469-77).

Influence of DNase Therapy on the Viability of Pancreatic Beta-Cells and Endothelium of Aorta

[0055] Human recombinant DNase I (Gentech) was used. .beta. cells of human embryonic pancreas and endothelial cells of human aorta were used for primary cell culture formation. DNA isolated from plasma of patient with severe form of diabetes mellitus type 2 that was complicated by atherosclerosis (0.0025 mkg on 1 ml of culture media) was added to one of the experimental series in cell culture 24 hours after passage and DNA extracted from the blood of the same patient but treated by DNase (1 mkg/ml; 37 C; 30 minutes) was added to the second series of cell culture. The number of viable cells was counted using the trypan blue uptake technique in a 24 hours.

[0056] Results of the experiment are presented in table 4:

TABLE-US-00005 TABLE 4 Percentage of viable cells 48 hours after their cultivation (in percents). DNA of DNA of patent Cells Control patient treated by DNse .beta. cells 73% 43% 61% Endotelium 62% 35% 55%

[0057] Thus extracellular blood plasma DNA of patient with severe form of diabetes mellitus type 2 and atherosclerosis negatively influence both the normal pancreatic .beta.-cells and the normal endothelial cells. Destruction of the patient' blood extracellular DNA prevents development of negative influence according to the claimed method.

Example 8

Isolation of Free Circulating DNA from Blood Plasma

[0058] Fresh blood plasma (not more than 3-4 hours after isolation) with anticoagulant (sodium citrate) addition was centrifuged on Ficoll-PlaquePlus (Amersham-Pharmacia) step at 1500 g for 20 minutes at room temperature. Plasma (1/2 of all amount) was neatly isolated avoiding touching cells sediment on ficoll step and was centrifuged at 10 000 g for 30 minutes to eliminate cells and debris. Supernatant was taken away not touching sediment and up to 1% of sarcosile, up to 50 mM of tris HCl pH 7.6, up to 20 mM EDTA, up to 400 mM NaCl and equal volume of phenolchloroform mixture 1:1 were added. Received emulsion was incubated at 65.degree. C. for 2 hours than phenol-chloroform was separated by centrifuging at 5000 g during 20 minutes at room temperature. Deproteinization by phenol-chloroform method was identically repeated for three times after what water phase was processed by chloroform and after it by diethyl ether.

[0059] Organic solvents' separation was done by centrifuging at 5000 g during 15 minutes. Equal part of isopropanol was added to water phase and incubated during night at 0.degree. C.

[0060] After sedimentation nucleic acids were separated by centrifuging at 10 000 g during 30 minutes. Sediment of nucleic acids was dissolved in buffer that consisted of 10 mM tris-HCl, pH 7.6, 5 mM EDT A and was inflicted on step made from chlorine cesium gradient (1M, 2.5M 5.7) in centrifuge test tube for SW60Ti rotor. DNA volume was 2 ml, volume of each CsCl step was 1 ml. Ultracentrifuging was done in L80-80 (Beckman) centrifuge for 3 hours at 250000 g. DNA was isolated according to fractions from the step's surface 5.7M. Fractions were dialized during 12 hours. mM tris-HCl, pH 7.6, 1 mM EDTA at 4.degree. C. will be added. DNA presence in fractions was defined by agarose electrophoresis with DNA visualization by ethidium bromide. DNA amount was spectrophotometric ally estimated (Beckman DU 470) in cuvette with volume 100 mkl, using 220-320 nm spectrum. Average runout of DNA was 10-20 ng according to 1 ml of plasma.

[0061] Cloning and sequencing of blood plasma DNA.

[0062] We have developed new method of DNA isolation and cloning from blood plasma, that allows to construct not amplified plasmide library of such DNA with representativeness up to million clones with average size 300-500 base pair isolated from 50 ml of blood, even taking into account significant amount of elevated liposaccharides level and non identified mixtures that troubled purification of nucleic acids. So representative analysis can be done with less amount of plasma pattern-10-20 ml depending on pathological contaminates' presence.

[0063] Isolated according to above-mentioned method DNA was deproteinized with the use of proteinase K (Sigma) at 65.degree. C. for tightly-bound proteins elimination. After deproteinization DNA was processed by phenol-chloroform at 65.degree. C. and sedimented by 2.5 volumes of ethanol during night. After it DNA was processed by EcoRI restrictase during 3 hours or by Pfu polymerase (Stratagene) at the presence of 300 mkM of all desoxynucleothydethreephosphates for "sticky" edges elimination. Completed DNA was phosphorylated by polynucleotide kinase T4 (30U, 2 hours). Received samples/preparations were ligated in Bluescript (Stratagene), plasmid digested by EcoR1 or PvuII accordingly and dephosphorylated by alkaline phosphatase CIP (Fermentas) during 1 hour. 1 mkg of vector and 0.1-0.5 mkg of serum DNA were usually used for ligation. Ligation was done by Rapid Ligation Kit (Roche) use for 10 hours at 16.degree. C. Volume of ligase mixture was 50 mkl. Ligated library was transformed into DH12S (Life Technologies) cells with electroporator (BioRad) use. For transformation of one library 12-20 electroporation cuvettes were used. Dilutions of the library at concentrations 10.sup.-4, 10.sup.-5 and 10.sup.-6 were plated for control on dishes with 1.5% agar and LB media, supplemented with 100 mkg\ml ampicillin. In both cases library's representativeness was approximately 2-3.times.10.sup.6 clones.

[0064] Theoretically set of DNA sequences that circulate in plasma should correspond to set of genome's DNA sequences. Usually cells apoptosis is accompanied by quantitative and nonspecific DNA degradation before its exit out of the cell, so the most wide spread DNA in plasma should be repetitive elements of genome in proportion that correspond to nonspecific degradation of DNA.

[0065] Such elements are L1 repeats, satellite DNA, Alu, MER, MIR, THE repeats and some others. Quantity of unique sequences should be small in accordance to their small percent in human genome they may be not detected in cloning DNA without PCR.

[0066] Blood plasma DNA library of oncological patient with clinically advanced tumor stage.

[0067] We have constructed blood plasma DNA library of patient with diagnosed advanced stage mesothelioma. Representativeness of library was 8.5.times.10.sup.5 clones, that is a good result, taking into account rather small amount of DNA (5 .mu.g) received after purification from non character for healthy donors liposaccharides that were in extremely high concentrations at plasma of patient.

[0068] We have got the unexpected results after analysis of 96 clones with length from 300 up to 1000 base pairs. (It is necessary to mention that only one clone was not identified as human DNA. For all others correspondent information from HumanGenBank that identifies DNA of these clones as human DNA was received.) As mentioned above, according to data from literature it is logically to assume that there will be a lot of highly repetitive elements in DNA samples.

[0069] But at least 55 out of 96 clones presented unique sequences of human DNA. Taking into account real ratio of repetitive and unique elements of human genome (95% to 5%) it is obvious that blood plasma DNA repertoire of this patient differs a lot from human genomic DNA repertoire. In this sample an abrupt enrichment by unique DNA sequences is observed.

[0070] For 15 out of 55 unique DNA fragments that were identified during sequencing of 96 clones from the library of blood plasma DNA, functions or product of correspondent gene were identified. Tables 1-15 present list of these sequences and information about their participation in formation and maintenance of "malignant phenotype".

TABLE-US-00006 TABLE 1 Clone Product Participation in oncogensis Source Clone Member of G Playing major role in cancer cell Steeg P. S., Nat 24 protein - coupled signalling. Linked with cell Rew receptor family transformation, supression of Cancer, 2003, v. 3, pp. apoptosis, hormone 55-63. independence and metastasis Raj G. V, J Urology, 2002, v. 167, pp. 1458-1463. Hoff A. O., Neoplasia, 1999 v. 1, pp. 485-491.

TABLE-US-00007 TABLE 2 Participation in Clone Product oncogensis Source Clone Snf2-coupled Transcription activator. Thaete c., Hum 43 CBP activator Family members linked Mol Genet, 1999, v. 8, protein with synovial sarcoma pp. 585-91. (SCRAP) and leukaemia Monroy M, A., J BioI development Chern,. 2001, v. 27 6, pp. 40721-40726 Lee D. W., Cancer Res., 2000, v. 60, pp. 3612-3622.

TABLE-US-00008 TABLE 3 Participation in Clone Product oncogensis Source Clone SRY-box Transcription modulator. Graham J. D., J 51 containing Expressed during Mol endocrinol, gene embryogenesis. 1999, v. 22, pp. Family members linked 295-304. with medulloblastomas, Lee C. J., J gonadal tumors, highly Neurooncol, metastatic melanoma. 2002, v. 57, pp. 201-214. Uehara S., Cancer Genet Cytogenet, 1999, v. 113., pp. 78-84. Tani M., Genomics, 1997, v. 39, pp. 30-37

TABLE-US-00009 TABLE 4 Participation in Clone Product oncogensis Source Clone Protein-tyrosine Family members Hunter T., Philos 72 kinase playing major role Trans R Soc Lond in cancer. B BioI Sci, Some PTK are 1998, v. 353., pp. cellular specific 583-605. oncogenes products. Scheijen B., Oncogene, 2002, v. 21., pp. 3314-3333.

TABLE-US-00010 TABLE 5 Participation in Clone Product oncogensis Source Clone Fibroblast Family members playing Chen W. T., 83 activation role in cancer invasion Enzyme protein alpha; and metastasis. Protein, 1996, v. 49., cell surface The product is active in pp. 59-71. serine protease cancer stroma and Scanlan M. J., Proc different carcinomas. Nat Acad Sci USA, 1994, v. 91, pp. 5657-5661. Mathew S., Genomics, 1995, v. 25, pp. 335-337.

TABLE-US-00011 TABLE 6 Participation in Clone Product oncogensis Source Clone Brain testican Proteoglycan with unknown Genini M., 86 function. lnt J Cancer, Linked with neoplastic 1996, v. 66, pp. phenotype of embryonal 571-577. rhabdomyosarcoma cells.

TABLE-US-00012 TABLE 7 Participation in Clone Product oncogensis Source Clone KRAB Family members are known as Oguri T., 152 domain, transcription repressers. Gene, 1998, v. 222, Zn-finger Linked with early pp. 61-67 proteins embryogenesis, Gou D. M., Biochim neuroblastoma, Ewing Biophys Acta, sarcoma, Tcell lymphoma, in 2001, v. 1518, pp. progression and 306-310 chemoresistance in lung Margolin J. F., Proc cancer. Nat Acad Sci USA, 1994, v/91, pp. 4509-4513. Bellefroid E. J., EMBO J, 1993, v. 12, pp. 1363-1374 Gonzales-Lamuno D., Pediatr Pathol Mol Med, 2002, v. 21, pp. 531-540. Marilee J. W., Gene, 1994, v. 152, pp. 227-232.

TABLE-US-00013 TABLE 8 Participation in Clone Product oncogensis Source Clone Antigen linked Antigen recognized by J. ImmunoI. 166(4), 190 with melanoma autologous tumor 2871-2877, 2001 infiltrating lymphocytes.

TABLE-US-00014 TABLE 9 Participation in Clone Product oncogensis Source Clone N-cadherin Cell adhesion molecule with Kazan R. B., J Cell 167 major role in cancer growth, BioI, invasion and metastasis. 2000, v. 148, pp. 779-790. Li G., Cancer Res, 2001, v. 61, pp. 3819-3825. Tran N. L., J BioI Chern, 2002, v. 277, pp. 32905-32914.

TABLE-US-00015 TABLE 10 Participation in Clone Product oncogensis Source Clone FAF1: Fas Phosphoprotein known Jensen H. H., Int J 197 associated to be the proapoptosis Biochem Cell BioI, factor 1 factor. 2001, v. 33, pp. 577-589. Ryu S. W., Biochem Biophys Res Commun,

TABLE-US-00016 TABLE 11 Participation in Clone Product oncogensis Source Clone Interleukin 7 Proposed as essential Trinder P., lnt J 114 paracrineautocrine Oneol, growth factor for variety of 1999, v. 14, pp. cancers. 23-31. Cosenza L., Cell Signalling, 2002, v. 14, pp. 317-325.

TABLE-US-00017 TABLE 12 Participation in Clone Product oncogensis Source Clone DEAD Family members Iggo R. D., Mol Cell 208 Box RNA involved to RNA BioI, helicase-like methabolism. Linked 1991, v. 11, pp. protein to exponential cell 1326-1333. growth in cancer. Causevic M., Oncogene, 2001, v. 20, pp. 7734-7743.

TABLE-US-00018 TABLE 13 Participation in Clone Product oncogensis Source Clone Lipin 1 One of tumor cells' response Brachat A. et. al., 97 regulators on cytotoxic Oncogene, compounds. 2002, v. 21, pp. 8361-8371

TABLE-US-00019 TABLE 14 Participation in Clone Product oncogensis Source Clone Dynein Takes part in transport of p53 Bull J. H., et. aI., Br J 121 protein, is hypersecreted at Cancer, 2001, v. 84, pp. cancer of prostate and 1512-1519. hepatocellular cancer. Giannakakou P., et. aI., Nat Cell BioI, 2000, v. 2, pp. 709-717 Jiang 1, et. aI., Gene, 2001, v. 281, pp. 103-113.

TABLE-US-00020 TABLE 15 Participation in Clone Product oncogensis Source Clone Ramp Linked with human embrional Cheung W. M., 178 protein carcinoma cells' development. et. aI., J BioI Chern, 2001, v. 276, pp. 17083-17091

[0071] In this way 14 out of 15 sequences with identified function or protein that encodes different products (protein kinases, growth factors, proteinases, adhesive molecules and regulatory nuclear proteins) are described in literature as related to "malignant phenotype" formation and maintenance. Only product of 197.sup.th clone identified as pro-apop-totic factor is not clearly linked with malignant progression. Though there is data concerning relationship between high apoptotic activity of tumor with its progression (Nishimura R., et al., J Surg Oncol, 1999, v. 71, pp. 226-234) and possible role of apoptotic inductors in formation and maintenance of immunosupression in malignant growth (O'Connel J., et al., Dis Esophagus, 1999, v. 12, pp. 83-89).

[0072] The most significant presence from repetitive elements in this material was alpha-satellite DNA (30 clones). It is possible to say that that alpha-satellite DNA was the only highly repeated element from human genome, which behaves exactly as repeat in this material. The rest of highly repetitive elements were presented in material as one or several clones (L1 variant and MLT26), or were not found among patterns (MER, Alu, THE, MIR, .beta.-satellite). Based on today's knowledge one can assume that plasma blood composition for the most part should repeat composition of genome DNA, so listed repeats should be represented in the major part of clones while unique and moderately repeated consequences in analysis of such a small number of clones should not be recognized at all. Received result clearly indicates on special way of plasma DNA formation in oncological patients. Another unexpected result is that of finding in the material of two new moderately repeated sequences--duplicones, that were recently unknown, also support the evidence of special way of plasma DNA formation in patients with malignant tumor. For the first time duplicones were found in human genome less then two years ago. Known duplicones (Eichler E. E., et al., Genome Res, 1998, v8, pp. 791-808; Ji Y, et al., Genome Res, 2000, v. 10, pp. 597-610; Pujana M. A., et al., Genome Res, 2001, v. 11, pp. 98-111) are extensive regions of DNA that were multi-plied for several times in the frame of one chromosome (unlike other repeats that are randomly allocated in genome). Duplicones' formation and expansion is connected with different genetic syndromes (for example Prader-Willi/An-gelmane syndrome), with multigenic families' evolution such as MHS (Shiina T., et al., Proc Nat Acad Sci USA, 1999, v. 96, pp. 13282-13287) and with chromosome instability in tumors.

[0073] It is necessary to mention that analysis of clones received from blood plasma DNA of patient has given us unexpected results.

[0074] Blood plasma DNA of oncological patient is highly enriched with unique genes. 55 out of 96 analyzed clones contain fragments of genome's unique sequences. 14 out of 15 sequences with identified in functions refer to process of tumor progression and maintenance of "malignant phenotype".

[0075] Strong impoverishment of the most wide spread human repeat such as MER, Alu, THE, MIR, .beta.-satellites is found in plasma DNA material.

[0076] Finding of two consequences with previously unknown duplicones' characteristics indicates on dupli-cones' representativeness in such DNA samples.

[0077] DNA library of healthy donor's blood plasma.

[0078] For method's value proof of blood plasma DNA cloning and sequencing for identification of genome's unique genetic consequences we have constructed DNA library of healthy donor's blood plasma. It is known that plasma of clinically healthy people also contains DNA but in significantly less amount than plasma of oncological patients (Shapiro B., et al., Cancer, 1983, v. 51, pp. 2116-2120).

[0079] Representativeness of library was near 8.times.10.sup.5 clones. We have got interesting result after analysis of 70 clones with length from 300 up to 1000 base pairs. We found out that 58 out of 70 analyzed clones are unique DNA sequences of human genome. After searching the HumanGenBank, we identified the function or product of correspondent gene for 14 out of 58 unique DNA fragments.

[0080] Only 12 clones contained fragments of repetitive sequences, herewith without of alpha-satellite DNA dominance.

[0081] So, it was unexpectedly found out that blood plasma DNA of healthy people and oncological patients for the most part contain unique fragments of human genome. In the case of oncological pathology unique sequences of blood plasma DNA correspond to genes which products take part in the formation and maintenance of tumor cell's "malignant phenotype".

[0082] Basing on this unexpected discovery we have suggested that DNA circulating in patient's blood can be messenger of horizontal genetic information transfer during the course of oncological diseases, assisting to accumulation and spreading of genes that are necessary for "malignant phenotype" formation and maintenance within population of tumor cells.

[0083] Somatic mosaicism is a condition that is a result of genetically non-identical somatic cells' presence in organism. Modern vision presents that many non tumor and noninfectious (so called somatic) human diseases (for example atherosclerosis, diabetes, nonspecific chronic lung diseases and so on), including aging process, are connected with appearance and spreading (expansion) in the process of individual development of somatic cells' clones that have mutant genes. (Youssoufian H., et al., Nature Rew. Genet., 2002, v. 3, pp. 748-758; J. Vijg, Mutation Res., 2000, v. 447, pp. 117-135; R. Erickson, Mutation Res., 2003, v. 543, pp. 125-136; Andreassi M., Mutation Res., 2003, v. 543, pp. 67-87; Anderson G., et al., Trends in Pharmacological Sci., 2003., v. 24, pp. 71-76).

[0084] Bright example of such process is progression of mitochondrial heteroplasmia (expansion of mutant mitochondrial DNA) at different diseases and in the aging process (E. Jazin et al., Proc Nat Acad Sci USA, 1996, v. 93, pp. 12382-12387; Michikawa Y. et al., Science, 1999, v. 286, pp. 774-779; Calloway C. et al., Am J Hum Gen, 2000, v. 66, pp. 1384-1397).

[0085] There are two alternative models of somatic mosaicism's appearance. The first is appearance of somatic mosaicism as a result of numerous "de novo" mutations in polyclonal cellular pool. The second model is clonal expansion of mutant cells' clone (Khrapko K., et al., Muation Res., 2003, v. 522, pp. 13-19).

[0086] In the process of work above the invention we have found that DNA circulating in the blood of healthy people play significant role in somatic mosaicism's development and its binding, destruction or inactivation inhibits development of somatic mosaicism. Binding, destruction or inactivation of circulating in blood plasma DNA provides treatment effect at diseases which appearance is connected with somatic mosaicism's development.

[0087] Examples that are mentioned later indicates role of circulating in blood of oncological patients DNA in the development of tumor's resistance to chemotherapy, development of metastasing process, in sepsis development and in some other pathological conditions. High therapeutic effect of blood plasma DNA's binding, destruction or inactivation is found.

Example 9

[0088] DNA Clones' Sequences, Received from Free Circulating Blood Plasma DNA of Patient with Malignant Mesothelioma

[0089] Clone 1

[0090] Duplicon, chromosome 15 and Y

[0091] Sequence No 1.

[0092] Clone 3

[0093] Unique, chromosome 2.

[0094] Sequence No 2

[0095] Clone 8

[0096] MLT2B repeat

[0097] Sequence No 3

[0098] Clone 9

[0099] Centromeric satellite DNA

[0100] Sequence No 4

[0101] Clone 10

[0102] MLT2B repeat

[0103] Sequence No 5

[0104] Clone 20

[0105] L1MC4-like (LINE-element)

[0106] Sequence No 6

[0107] Clone 15

[0108] Alpha-satellite DNA

[0109] Sequence No 7

[0110] Clones 18, 21

[0111] Alpha-satellite DNA

[0112] Sequence No 8

[0113] Clone 24

[0114] Unique, family of G protein-bound proteins, chromosome 6.

[0115] Sequence No 9

[0116] Clone 25

[0117] Unique, chromosome 3.

[0118] Sequence No 10

[0119] Clone 26

[0120] SatB1/Vimentin/nuclear matrix binding DNA

[0121] Sequence No 11

[0122] Sequence 33

[0123] Duplicon specific to the chromosome 10

[0124] Sequence No 12

[0125] Clone 32

[0126] alpha-satellite DNA

[0127] Clone 35

[0128] LTR repeat

[0129] Sequence No 13

[0130] Clone 36

[0131] Unique, chromosome 18

[0132] Sequence No 14

[0133] Clone 37

[0134] Unique, chromosome 4

[0135] Sequence No 15

[0136] Clone 41

[0137] Sequence No 16

[0138] Clone 43

[0139] Snf2-related CBP activator protein (SCRAP)

[0140] Unique, chromosome 16

[0141] Sequence No 17

[0142] Clone 45

[0143] Unique, chromosome 3

[0144] Sequence No 18

[0145] Clone 47

[0146] Alpha-satellite DNA

[0147] Clone 51

[0148] SRY-box containing gene.

[0149] Sequence No 19

[0150] Clone 52

[0151] Repeat

[0152] Sequence No 20

[0153] Clone 53, 55

[0154] Alpha-satellite DNA

[0155] Sequence No 21

[0156] Clone 56

[0157] Centromeric repeat

[0158] Sequence No 22

[0159] Clone 60

[0160] Gene repeated on several chromosomes, contains MER5A repeat.

[0161] Sequence No 23

[0162] Clone 62

[0163] Repeat

[0164] Sequence No 24

[0165] Clone 65

[0166] Unique, chromosome 2

[0167] Sequence No 25

[0168] Clone 71

[0169] Unique, chromosome 2

[0170] Sequence No 26

[0171] Clone 72

[0172] Unique, chromosome 8

[0173] Sequence No 27

[0174] Clone 73

[0175] Unique

[0176] Sequence No 28

[0177] Clone 78

[0178] Transposon Tigger fragment

[0179] Sequence No 29

[0180] Clone 81

[0181] Sequence No 30

[0182] Repeat (LINE)

[0183] Clone 82

[0184] Unique, chromosome 1

[0185] Sequence No 31

[0186] Clone 83

[0187] Unique, Fibroblast activation protein alpha; cell surface serine protease

[0188] Chromosome 2

[0189] Sequence No 32

[0190] Clone 79

[0191] Alpha-satellite DNA

[0192] Clone 86

[0193] Unique, gene highly similar to brain testican, chromosome 4.

[0194] Sequence No 33

[0195] Clone 90

[0196] Unique, chromosome X

[0197] Sequence No 34

[0198] Clone 93

[0199] Unique, chromosome 9

[0200] Sequence No 35

[0201] Clones 89 and 92

[0202] Alpha-satellite DNA

[0203] Clone 96

[0204] Fragment LINE.

[0205] Sequence No 36

[0206] Clone 97

[0207] Chromosome 2 unique, Lipin

[0208] Clone 98

[0209] Unique, chromosome X

[0210] Sequence No 38

[0211] Clone 102

[0212] Chromosome 17 unique

[0213] Sequence No 39

[0214] Clone 99

[0215] Alpha-satellite DNA

[0216] Clone 105

[0217] Unique, chromosome 13

[0218] Sequence No 40

[0219] Clone N106

[0220] Chromosome 9 unique

[0221] Sequence No 41

[0222] Clone 107

[0223] Unique, chromosome 8

[0224] Sequence No 42

[0225] Clone N 111

[0226] Unique, chromosome 12

[0227] Sequence No 43

[0228] Clone N 112

[0229] Chromosome 5 unique

[0230] Sequence No 44

[0231] Clone 114

[0232] Chromosome 8 unique; Interleukin 7

[0233] Sequence No 45

[0234] Clone 116

[0235] Chromosome 1 unique

[0236] Sequence No 46

[0237] Clone 121

[0238] Chromosome 5 unique; Dynein

[0239] Sequence No 47

[0240] Clone 115; 119; 120

[0241] Alpha-satellite DNA

[0242] Clone 125

[0243] Chromosome 9 unique

[0244] Sequence No 48

[0245] Clone 127

[0246] Unique chromosome 20

[0247] Sequence No 49

[0248] Clone 130

[0249] Unique, chromosome is not determined.

[0250] Sequence No 50

[0251] Clone 124

[0252] SatB1/Vimentin/nuclear matrix binding DNA

[0253] Clone 133

[0254] Alpha-satellite DNA

[0255] Clone 137

[0256] MLT1A2 repeat

[0257] Sequence No 51

[0258] Clone 140

[0259] Unique, chromosome 2; zinc finger protein, sub-family 1A

[0260] Sequence No 52

[0261] Clone 141

[0262] Chromosome 2 unique

[0263] Sequence No 53

[0264] Clone 143

[0265] Fragment of Alu-repeat

[0266] Sequence No 54

[0267] Clone 144

[0268] Chromosome 2 unique

[0269] Sequence No 55

[0270] Clone 146

[0271] Chromosome 4 unique

[0272] Sequence No 56

[0273] Clone 139 and 142

[0274] Alpha-satellite DNA

[0275] Clone 148

[0276] Repeat (chromosomes 1, 2 and 4)

[0277] Sequence No 57

[0278] Clone 152

[0279] Unique, chromosome 16; KRAB-Domain, zinc finger protein

[0280] Sequence No 58

[0281] Clone 154

[0282] Chromosome 9 unique

[0283] Sequence No 59

[0284] Clone 161

[0285] Fragment LINE

[0286] Sequence No 60

[0287] Clone 151

[0288] Chromosome 5 unique

[0289] Sequence No 61

[0290] Clone 150

[0291] Chromosome 1 unique

[0292] Sequence No 62

[0293] Clone 153

[0294] Chromosome 11 unique

[0295] Sequence No 63

[0296] Clone 159

[0297] Chromosome 6 unique

[0298] Sequence No 64

[0299] Clone 163

[0300] Alpha satellite DNA

[0301] Sequence No 65

[0302] Clone 166

[0303] Chromosome 12 unique

[0304] Sequence No 66

[0305] Clone 167

[0306] Unique, chromosome 18, CDH2; cadherin 2, type 1, N-cadherin

[0307] Sequence No 67

[0308] Clones 169, 170

[0309] Chromosome 18 unique

[0310] Sequence No 68

[0311] Clone 178

[0312] Unique chromosome 1; RAMP: RA-regulated nuclear matrix-associated protein

[0313] Sequence No 69

[0314] Sequence No 69

[0315] Clone 180

[0316] Unique, chromosome 20

[0317] Sequence No 70

[0318] Clone 181

[0319] Unique chromosome 18

[0320] Sequence No 71

[0321] Clone 185

[0322] Alpha-satellite DNA

[0323] Sequence No 72

[0324] Clone 187

[0325] Mer repeat

[0326] Sequence No 73

[0327] Clone 188

[0328] HSATII repeat

[0329] Sequence No 74

[0330] Clone 189

[0331] Chromosome 9 unique

[0332] Sequence No 75

[0333] Clone 190

[0334] Chromosome 1 unique; melanoma antigen recognized by T cells 2

[0335] Sequence No 76

[0336] Clone 195

[0337] Chromosome 10 unique

[0338] Sequence No 77

[0339] Clone 196

[0340] Chromosome X unique

[0341] Sequence No 78

[0342] Clone 197

[0343] Chromosome 1 unique, FAF 1: Fas (TNFRSF6) associated factor 1

[0344] Sequence No 79

[0345] Clone 200

[0346] Chromosome 8 unique

[0347] Sequence No 80

[0348] Clone 202

[0349] Unique chromosome 13

[0350] Sequence No 81

[0351] Clone 205

[0352] Alpha satellite DNA

[0353] Sequence No 82

[0354] Clone 206

[0355] Repeat

[0356] Sequence No 83

[0357] Clone 208

[0358] Unique chromosome 8; Human DEAD box RNA helicase-like protein

[0359] Sequence No 84

Example 10

DNA Clones Sequences Received from Free Circulating Blood Plasma DNA of Healthy Donor

[0360] Clone 1

[0361] Chromosome 5 unique

[0362] Sequence No 85

[0363] Clone 9

[0364] Unique chromosome 21

[0365] Sequence No 86

[0366] Clone 7

[0367] Unique chromosome 3

[0368] Sequence No 87

[0369] Clone 8

[0370] Chromosome 4 unique

[0371] Sequence No 88

[0372] Clone 10

[0373] 18S RNA gene

[0374] Sequence No 89

[0375] Clone 11

[0376] Alu repeat

[0377] Sequence No 90

[0378] Clone 13

[0379] Unique chromosome 3

[0380] Sequence No 91

[0381] Clone 15

[0382] Unique chromosome 1

[0383] Sequence No 92

[0384] Clone 16

[0385] Unique chromosome 3, neutral endopeptidase

[0386] Sequence No 93

[0387] Clone 17

[0388] Chromosome 8 unique

[0389] Sequence No 94

[0390] Clone 18

[0391] Chromosome 1 unique

[0392] Sequence No 95

[0393] Clone 21

[0394] Unique chromosome 19; Zinc Finger protein

[0395] Sequence No 96

[0396] Clone 22

[0397] Unique chromosome 18

[0398] Sequence No 97

[0399] Clone 23

[0400] Unique chromosome 7, muskelin 1

[0401] Sequence No 98

[0402] Clone 25

[0403] Unique chromosome 11

[0404] Sequence No 99

[0405] Clone 27

[0406] Repeat

[0407] Sequence No 100

[0408] Clone 29

[0409] Unique chromosome 6

[0410] Sequence No 101

[0411] Clone 30

[0412] Unique chromosome 14

[0413] Sequence No 102

[0414] Clone 31

[0415] Unique chromosome 17

[0416] Sequence No 103

[0417] Clone 32

[0418] MER4B repeat

[0419] Sequence No 104

[0420] Clone 33

[0421] Chromosome 1 unique

[0422] Sequence 105

[0423] Clone 34

[0424] Unique chromosome 2

[0425] Sequence 106

[0426] Clone 35

[0427] Repeat

[0428] Sequence 107

[0429] Clone 36

[0430] Chromosome 1 unique

[0431] Sequence No 108

[0432] Clone 37

[0433] HERVH repeat

[0434] Sequence No 109

[0435] Clone 41

[0436] Chromosome X unique

[0437] Sequence No 110

[0438] Clone 42

[0439] Chromosome 6 unique

[0440] Sequence No 111

[0441] Clone 43

[0442] Unique chromosome 22; KREMEN1

[0443] Sequence No 112

[0444] Clone 44

[0445] Unique chromosome 14

[0446] Sequence No 113

[0447] Clone 45

[0448] Unique

[0449] Sequence No 114

[0450] Clone 46

[0451] Chromosome 20 unique

[0452] Sequence No 115

[0453] Clone 47

[0454] Nf-kappaB

[0455] Sequence No 116

[0456] Clone 38

[0457] Unique chromosome 16

[0458] Sequence No 117

[0459] Clone 48

[0460] Chromosome 6 unique

[0461] Sequence No 118

[0462] Clone 53

[0463] Unique

[0464] Sequence No 119

[0465] Clone 51

[0466] Chromosome 5 que

[0467] Sequence No 120

[0468] Clone 59

[0469] Unique chromosome 4, NFKB 1: nuclear factor of kappa light polypeptide gene enhancer

[0470] Sequence No 121

[0471] Clone 61

[0472] Repeat

[0473] Sequence No 122

[0474] Clone 62

[0475] L1 repeat

[0476] Sequence No 123

[0477] Clone 64

[0478] Duplicon chromosome 7

[0479] Sequence No 124

[0480] Clone 65

[0481] Ribosomal DNA

[0482] Sequence No 125

[0483] Clone 66

[0484] Rbosomal DNA

[0485] Sequence No 126

[0486] Clone 75

[0487] Repeat

[0488] Sequence No 127

[0489] Clone 76

[0490] Chromosome 4 unique

[0491] Sequence No 128

[0492] Clone 83

[0493] Chromosome 4 unique

[0494] Sequence No 129

[0495] Clone 85

[0496] Unique chromosome 2; phospholipase C, epsilon

[0497] Sequence No 130

[0498] Clone 87

[0499] L1PA3 repeat

[0500] Sequence No 131

[0501] Clone 86

[0502] Unique chromosome 5; CRTL 1: cartilage linking protein 1

[0503] Sequence No 132

[0504] Clone 89

[0505] Alu repeat

[0506] Sequence No 133

[0507] KOH 92

[0508] Unique chromosome 6

[0509] Sequence No 134

[0510] Clone 100

[0511] Unique, chromosome 6

[0512] Sequence No 135

[0513] Clone 105

[0514] AluSx repeat

[0515] Sequence No 136

[0516] Clone 111

[0517] Alphoid repetitive DNA

[0518] Sequence No 137

[0519] Clone 112

[0520] Chromosome 9 unique

[0521] Sequence No 138

[0522] Clone 113

[0523] Chromosome 22 unique

[0524] Sequence No 139

[0525] Clone 114

[0526] AluSx repeat

[0527] Sequence No 140

[0528] Clone 116

[0529] Unique chromosome 9; 17 kD fetal brain protein

[0530] Sequence No 141

[0531] Clone 123

[0532] Unique chromosome 5

[0533] Sequence No 142

[0534] Clone 124

[0535] Unique chromosome 13

[0536] Sequence No 143

[0537] Clone 126

[0538] Unique chromosome 8

[0539] Sequence No 144

[0540] Clone 130

[0541] Unique chromosome 1

[0542] Sequence No 145

[0543] Clone 131

[0544] Unique chromosome 4

[0545] Sequence No 146

[0546] Clone 136

[0547] Unique chromosome 8

[0548] Sequence No 147

[0549] Clone 141

[0550] Unique chromosome 2

[0551] Sequence No 148

[0552] Clone 146

[0553] Unique chromosome 16

[0554] Sequence No 149

[0555] Clone 147

[0556] Unique chromosome 5; nicotinamide nucleotide transhydrogenase

[0557] Sequence No 150

[0558] Clone 149

[0559] Unique chromosome 9

[0560] Sequence No 151

[0561] Clone 151

[0562] Unique chromosome 16

[0563] Sequence No 152

[0564] Clone 152

[0565] Unique chromosome 6, BA13: brain-specific angiogenesis inhibitor 3

[0566] Sequence No 153

[0567] Clone 153

[0568] Unique chromosome 9, GAD2: glutamate decarboxylase 2

[0569] Sequence No 154

[0570] Clone 155

[0571] Unique chromosome 9

[0572] Sequence No 155

Example 11

Dynamics of P-Glycoprotein Expression in Erlich Carcinoma in Mice that Receive Doxorubicin Therapy and DNase I Effect

[0573] Treatment by Doxorubicin causes expression of P-glycoprotein in tumor tissue that is one of the main MDR (Multi drug Resistance) phenotype mediators. Immunohistochemical staining of mice's tumor histological cuts are listed below.

[0574] Mice were subjected to course of 5 day therapy with Doxorubicin (2 mg/kg intravenously daily) or Doxorubicin+DNase I (0.5 mg/kg four times a day during 5 days)

[0575] Treatment has begun on the 3.sup.rd day after tumor's transplantation. Tissue preparations were executed on the 8th day of tumor's transplantation. Multifocal expression of P-glycoprotein was observed in tumor tissue after 5 days of therapy (FIG. 3).

[0576] Total level of P-glycoprotein expression and amount of P-glycoprotein positive nodules in tumor tissue was much lower at the case of combined treatment by Doxorubicin+DNase (FIG. 3). So treatment by DNase delays development of multidrug resistant phenotype in tumor that is caused by antitumor antibiotic Doxorubicin use.

Example 12

Influence of Plasma DNA of C57B1 Mice with LLC Tumor after Chemotherapeutical Treatment by Doxorubicin, on LLC Tumor Growth and Metastasizes Development at C57B1 Mice Receiving Doxorubicin Therapy and Effect of DNase I

[0577] LLC tumor was replanted to 30 C57B1 mice. Twenty mice were treated with Doxorubicin at 2 mg/kg dose daily for 5 days, starting day 3 after transplantation. Ten mice were treated with Cyclophosphamide at 15 mg/kg dose intraperitoneally for once on the 3.sup.rd day after replantation. Such treatment scheme does not lead to animal's recovery but leads to 50% tumor inhibition at day 8 in doxorubicin treated animals and 30% tumor inhibition at day 8 in Cyclophosphamide treated animals. On the next day after end of chemotherapy course animals were euthanized and total blood plasma from both mice groups was taken. After isolation total fraction of blood plasma DNA was stored at -20.degree. C. in phosphate buffer.

[0578] Five groups of mice that were transplanted with LLC tumor participated in experiment.

[0579] Group 1-7 mice (control).

[0580] Group 2-6 mice intravenously treated with Doxorubicin chemotherapy from 3.sup.rd up to 8.sup.th day at 2 mg/kg dose daily.

[0581] Group 3-6 mice intravenously treated with Doxorubicin chemotherapy from 3.sup.rd up to 8.sup.th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to Doxorubicin chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)

[0582] Group 4-6 mice intravenously treated with Doxorubicin chemotherapy from 3.sup.rd up to 8.sup.th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to cyclophosphamide chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)

[0583] Group 5-6 mice intravenously treated with Doxorubicin chemotherapy from 3.sup.rd up to 8.sup.th day at 2 mg/kg dose daily+intravenous administration of DNA fraction from mice previously subjected to Doxorubicin chemotherapy (0.05 mkg of DNA in 200 mkl of phosphate buffer at day 1 and day 3 after initiation of treatment)+intraperitoneal administration of DNase I at 0.5 mg/kg dose for 4 times a day at the first and second days of treatment.

[0584] Tumor's size on the 8.sup.th day after transplantation.

TABLE-US-00021 Group Tumor's size 1 127 +/- 13 2 67 +/- 7 3 115 +/- 20 4 75 +/- 11 5 82 +/- 9

[0585] So administration of blood plasma DNA from mice subjected to chemotherapy lead to tumor's resistance to chemotherapeutic treatment. DNase's administration prevents appearance of this effect.

Example 13

Influence of Blood Plasma DNA from C57B1 Mice with Highly Metastatic LLC Strain on Metastasizing of Low Metastatic LLC Tumor Strain in C57B1 Mice and Effect of DNase I

[0586] LLC tumor was transplanted to 30 C57B1 mice. Twenty mice were transplanted with highly metastatic strain and 10 mice were transplanted with low metastatic strain. On the 9th day animals were euthanized and total blood plasma of both mice groups was collected. After isolation the total fraction of blood plasma DNA was stored at -20.degree. C. in phosphate buffer.

[0587] Five groups of mice with transplanted LLC tumor participated in the experiment.

[0588] 1 Group-6 mice transplanted with low metastatic LLC strain.

[0589] 2 Group-6 mice transplanted with low metastatic LLC strain+intravenous administration of total DNA fraction from mice with transplanted highly metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7.sup.th and 8.sup.th day after transplantation).

[0590] 3 Group-6 mice transplanted with low metastatic LLC strain+intravenous administration of total DNA fraction from mice with transplanted low metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7.sup.th and 8.sup.th day after transplantation)

[0591] 4 Group-6 mice transplanted with low metastatic LLC strain+intravenous administration of total DNA fraction from mice with transplanted highly metastatic strain (0.05 mkg of DNA in 200 mkl of phosphate buffer on the 7.sup.th and 8.sup.th day after transplantation)+intraperitoneal administration of DNase I at 1 mg/kg dose two times daily at 7.sup.th and 8.sup.th day after transplantation.

[0592] 5 Group-6 mice transplanted with highly metastatic LLC strain.

[0593] Number of metastatic foci in lungs was estimated on the 15.sup.th day after transplantation (N).

[0594] Experiments' results are presented in the table.

TABLE-US-00022 Group N 1 12, 0 2 24, 1 3 14, 6 4 11, 6 5 33, 6

[0595] Received data indicates that blood plasma DNA from mice with highly metastatic LLC strain intensify metastasizing of low metastatic LLC strain.

[0596] DNase administration prevents appearance of this effect.

Example 14

DNase I Influence on Life Span of C57B1 Mice Transplanted with LLC Tumor (Highly Metastatic Strain)

[0597] Five groups of LLC transplanted mice participated in the experiment.

[0598] Group 1-7 mice (control).

[0599] Group 2-6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 7 day after tumor transplantation.

[0600] Group 3-6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 10 day after tumor transplantation.

[0601] Group 4-6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 15 day after tumor transplantation.

[0602] Group 5-6 mice were treated with intraperitoneal administration of DNase at 1 mg/kg dose two times a day starting from 3 up to 18 day after tumor transplantation.

[0603] Results of experiment were estimated according to animals' survival on the 30 and 50 day after tumor transplantation.

TABLE-US-00023 30 day 50 day (number of (number of alive\number of alive\number of Group dead in group) dead in group) 1 0-7 0-7 2 0-6 0-6 3 3-6 0-6 4 5-1 3-3 5 6-0 6-0

[0604] The significant inhibition of tumor's growth was observed at the last day of DNase treatment in the 2nd and 3rd groups, but tumor's growth renewed after DNase withdrawal and to the 25.sup.th day size of tumor in this groups and in control has equalized.

[0605] The most longitudinal course of DNase treatment (from 3.sup.rd up to 18th day-group number 6) has lead to maximal survival. Inhibition of tumor growth was more than 95% at day 18.

[0606] In all experiments single and multiple injection of up to 2.5 mg/kg of human DNase I (maximal dose that was used in experiments) had no toxic effect on animals.

[0607] So, DNase I does not cause direct cytotoxic effect on tumor cells (in our in vitro experiments at concentration of 100 mkg/ml) and experimental data confirm that antitumor effect is connected with destruction of DNA in blood plasma and DNase's therapeutic effect increases with increasing of its treatment course duration.

Example 15

Influence of Different Methods of Blood Plasma DNA's Destruction, Inactivation, and Binding on Ability of Blood Plasma DNA from C57B1 Mice with Transplanted Highly Metastatic LLC Strain to Intensify Metastasizing of Low Metastatic LLC Tumor Strain in C57B1 Mice

[0608] 100 mice were transplanted with highly metastatic LLC strain. On the 9th day after transplantation, animals were euthanized and total blood plasma was taken. After isolation total fraction of blood plasma DNA was stored at -20.degree. C. in phosphate buffer.

[0609] Six groups of mice with transplanted low metastatic LLC strain participated in the experiment.

[0610] Group 1-6 mice transplanted with low metastatic LLC strain.

[0611] Group 2-6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection).

[0612] Group 3-6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh blood plasma before injection). Before administration the sample was photochemically disinfected (1 mkM of methylene blue was added with following irradiation by red light during 10 minutes (60 000 Lux).

[0613] Group 4-6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh blood plasma before injection). The sample was passed through the column containing DEAE-cellulose for two times before administration.

[0614] Group 5-6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection. 1 mkg of fragment A of Ricin toxin was added to the sample before administration and sample was incubated at 370 C for 1 hour. Ricin toxin is representative of RIP toxins family (proteins that inactivate ribosomes) which are used for immunotoxin's creation. Besides their ability to inactivate ribosomes these proteins can deadenylate DNA. For realization of toxic effect catalytic subunit A of RIP II type should by delivered to cell by B subunit. Without B subunit A chain is not toxic but can be used for blood plasma DNA's inactivation due to its polynucleotide-adenylglicozidase activity.

[0615] Group 6-6 mice transplanted with low metastatic LLC strain+two intravenous injections of total DNA fraction from mice transplanted with highly metastatic strain on the 7th and 8th day after transplantation (0.05 mkg of DNA was dissolved in 500 mkl of fresh heparinized blood before injection. Total DNA fraction was enzymatically methylated before administration (I. Muiznieks et. al., FEBS Letters, 1994, v. 344, pp. 251-254).

[0616] Number of metastaic nodules in lungs was estimated on the 15th day after transplantation.

[0617] Results of the experiments are presented in the table.

TABLE-US-00024 Group Ncp. 1 12, 0 2 22, 5 3 14, 1 4 15, 5 5 15, 1 6 12, 3

[0618] Received data indicates that all used methods inhibited ability of blood plasma DNA of mice with highly metastatic LLC tumor strain to increase metastasizing process of low metastatic LLC tumor strain.

INDUSTRIAL APPLICABILITY

[0619] For the realization the methods there were used well-known materials and equipment manufactured in plant conditions and according to aforesaid the invention conformances to requirements of "industrial applicability" criteria (IA).

Sequence CWU 1

1

1551484DNAHomo sapiens 1cgacggccag tgagcgcgcg taatacgact cactataggg cgaattgggt accgggcccc 60ccctcgaggt cgacggtatc gataagcttg atatcgaatt ctgaccaccc caaggtggcc 120atccttgtcc ctgtgattcc agatctccag aactggaggt ctagcttcag ggaaaaccca 180gattttcttg gcttagccca cctgacagct aatcactgga aatggggtgg gctggtagag 240tcctttggtc aggttttgtg tcaagagagg gaggaggaaa gatgggaggg aggtagcaaa 300actggtctca atggaactat gtaagttaat atagaatggc aaagggatgt ttcttccaag 360gaaagaattc ctgcagcccg ggggatccac tagttctaga gcggccgcca ccgcggtgga 420gctccagctt ttgttccctt tagtgagggt taattgcgcg cttggcgtaa tcatggtcat 480agct 4842244DNAHomo sapiens 2gaattctcaa attattactg aggaaaatgt gacagtgctt caaagcagta gtaatttttt 60ctcattatgc tgcatttatt attaaaacca acagtggaca gtgaatgact aactgatcct 120tttttgggaa tattacttcc aaatgaacgt taacttaaag attggaatat gaacacacta 180ttgcttttac actagagagg ttactcctgg ccactctttc agcagcagtt agcttcagga 240attc 2443230DNAHomo sapiens 3gaattcgcag taacttcctt gtgttgtgtg tattcaactc acagagttga acgatcgttt 60acacagagca gacttgaaac actctttttg tggaatttca agtggagatt tcaattgttt 120gaggtcaatg gtagaatagg aaatatcttg ctatagaaac tagacagaat gattctcaga 180aactcctttg tgatgtgtgc cttcaactca cagagtttaa cctttctttt 2304218DNAHomo sapiens 4gaattctcat gaaattgaaa tggatggact catcatcgaa tggattcgaa tggaatcatc 60gaataaaatt gattgagaat catcatcaaa tggaatcgaa tggtatcatt gaatggaatc 120gaatggaatc atcatcagat ggaaatgaat ggaatcgtca tagaatccaa tcgaatggat 180tcattgaatg gaatcagatg gaatcatcga gtgactga 2185182DNAHomo sapiens 5gaattctcta cagggacaga actaatggaa tatatgtatt atacagggga gtttattaaa 60cattaactca catgatcaca aggtcccgca ataggctgtc tgcaggcagg ggcgaaggag 120gccagtgaag ttccaaaact caagaaccta gagtcaatgt tcaagggcga ggaagcatcc 180ag 1826152DNAHomo sapiens 6gaattcacag aaatcattgc cacaggcaag atctgatgaa ccttgatgaa tgctaaaatt 60agttggtgaa agtttaagca gaaacagaat gtttgcatag aatgaagcaa aagaaggaaa 120aaaaattatg agcccttgat ttaggggtct tt 1527131DNAHomo sapiens 7gaattcttct gtctagagta acatgaagaa atcccgtttc caacgaaggc cctcaaggcg 60gtcaattatc cacttcgaga ttctacagaa agagtgtttc aaaactgctc tatcaagaga 120aatgttccac c 1318239DNAHomo sapiens 8gaattcccag taacttcctt gtgttgtgta cattcaactc acagagttga acgttccctt 60agacagagca gatttgaaac actctttttg tgcaattggc aagtggagat ttcaagcgct 120ttaaggtcaa tggcagaaaa ggaaatatct tcgtttcaaa actagacaga atcattccca 180caaactgcgt tgtgatgtgt tcgttcaact cacagagttt aacctttctt ttcatagag 2399207DNAHomo sapiens 9gaattctcta gacttccttg ggtttagcgc tgagtgaaga ggcacggaga gggtttggag 60ctttagggta aagcactgat ggaagaaagg aattcctgca gcccggggga tccactagtt 120ctagagcggc cgccaccgcg gtggagctcc agcttttgtt ccctttagtg agggttaaaa 180gcgcgcttgc gtaatcatgg tcatagc 20710223DNAHomo sapiens 10gaattcatcg ctaggactgt gttcttgttt attgggatgg gaagggagag aaaagatgag 60aggggcaaaa gagaaaattt tggaaaatga gaaacttact ttattgcact gtctgtgcaa 120ttgttggtct taaggaacaa atacactaaa ttcaaagatg ataaaaaaaa aaaacagctt 180cacagagctg tagtaaacac cagatgttga aagagaagcg tat 22311198DNAHomo sapiens 11gaattccatt tgatgacaat tccattcaat accaattgat gatgtttatt tttgattcca 60tttgatgatg attacattcg attccatttc atcatgattc cattcgattc cactcgatga 120ttccattcga ttccattcaa tgattattcc acttgagtcg attcgatgac tccattcgat 180tgtattcgat ggtgattg 19812217DNAHomo sapiens 12gaattctgcc aagcagtgac ttgattcatg aacactcact ggatgctgac tctgttgctc 60ttctgagtgc tggggtagag gagaggatga ggtggacgca cagttcttgc ttttatgagc 120ttatgttcta ggaaattcaa acaagtattt tttcaggcag gtagtatgaa atagcaggaa 180gaggaagcag gctaaaggga cacagagtga ttggggg 21713223DNAHomo sapiensmodified_base(129)..(129)a, c, t or g 13gaattcaggg ctgcagaaat ttgtgtaagt aaagaggagc agaatgttaa tagccaagac 60aatgcaaaaa atgcattcaa ggtgttttga aaccttcatg gtagcccctc ccattacaag 120cctggaggnc tgggagggaa aaataatccc tgaaccagga caagggccct atccctattt 180ctctgtacag tctcaggaca cagcactttg catcccagca gct 22314258DNAHomo sapiens 14gaattcgctt acagtcagtt acaaatgctt tttagatctt caatgcttct gtgaagcctc 60atatttgctg ttcagacaga cactataatg gagatggaat aaatggacag caactacaca 120ggacggtgtg ggcagatggt gttggagcga ggggtgcagg tggagcccac aggagaggaa 180ggctgattga tcttctatgg ggagagcttc atagcacggg ggtggggcac acctgactgg 240caagctgttt ggtgtgag 25815239DNAHomo sapiens 15gaattctttt gaactagctg tgttttgaca gaggtttttt tttttttttt tctttttttg 60gttttttgct tctctgacaa aggcctttgg aagaatgagc ttcttccccc acatctttat 120ttatttattt atttttaagc tatgctcagg aaaatgaaca tttctccttt gcagttgata 180acagcattta caaggtatac agcatatagg gttgttccaa attccttccc agataacca 23916236DNAHomo sapiens 16gaattcctga atggtggggg gactgtgtgt ctctggccct attccctctc caggacaaac 60ctcacccttt cctgcaaatg tactcaaaat agtacattta tccacgtcaa ttcagcaaag 120gctgcagatc ctgggactac agtatctcag acgctgttct cagcgagctc atggtccagt 180ggagagcaca gacaaacagc aaggcaggag aaatcgcctc tgaagagccc agggag 23617156DNAHomo sapiens 17gaattcagcc gtggcagtga gatggagtgt gtgtttagaa ctgttgattg atctggctct 60ccctgattag gaggccgaga tcgagactcg gattgctgag ctgcggaagg agggtttctg 120gtcactgaag aggctgccta aggtgccaga gccccc 15618191DNAHomo sapiens 18gaattctaca aaagaaataa agcagagatg tgaaaggaat ttcttcaact atacacattt 60tgacataatc atcttctaac atggtgttta atttgctctg cttcacttag caatgatata 120atgaatattt cccattttat tatatattct acaatatcac tttgaatgac tctcttaaga 180gtgtattata c 19119312DNAHomo sapiens 19cgacggccag tgagcgcgcg taatacgact cactataggg cgaattgggt accgggcccc 60ccctcgaggt cgacggtatc gataagcttg atatcgcttg tgggctgaag gatgcaattc 120tagacagagt tagctgggaa tgcctcactg agaaggggcc atttgagtaa aggcctgaaa 180aggtgaagaa gaattcctgc agcccggggg tccactagtt ctagagcggc cgccaccgcg 240gtggagctcc agcttttgtt ccctttagtg agggttaatt gcgcgcttgg cgtaatcatg 300gtcatagctg tt 31220219DNAHomo sapiens 20gaattccagt ggaatcagtt gtaatgtctc ctttttcata tctgatttta tttagtgtct 60ttttttctta gatagtcttg ctaaaggttt ctcaatttat cttttcaaaa aatcttttca 120ttttgttgat cttttttatt attttcttca tttcattttt atttatttct gctctgatct 180ttattatttc ttttcttcta ataattttgg gtttagttt 21921208DNAHomo sapiens 21gaattctcag taacttcctt gtgttgtgtg tattcaactc acagagttga acgatccttt 60acacagagcg gacttgaaac actctttttg tggaatttgc aagtggagat ttcagccgcg 120ttgaggtcaa tggtagaaaa ggaaatatct tcgtataaaa actagacaga atgattctca 180gaaactcctt tgtgatgtgt gtgttcaa 20822262DNAHomo sapiens 22gaattcaatg gaatggaatg gacaggaatg gaatggaatg gaaaggaatg gagtggaatg 60gactagaatg gaatggaatg gaatgaaatc aacccgattg gaatggaatg gaatgcaatg 120gaatggaatg gaatcaactg gaaaggaatc aaatagaacg gaatggaata gaatggaatg 180gattggaatg gaatggaatg gattcaaccc gagtggaatg gaatggaata gaatggaata 240aacaacgagt ggaatggaat gg 26223218DNAHomo sapiens 23gaattcgttg aggagcttct ggaaagtgca cattctgact cagcaggtat tggagtctgc 60atttctcatg agcactcagg tgatgaaaga gctggtcctt ggacacagct ctgaatagca 120agggaatagc tttcctttag agaaatctgg aaaaagaacc actggagagc aatttaaaaa 180ataacagaat ccagggaaag ctttaatttc cttttatt 21824213DNAHomo sapiens 24gaattcaaag gaatcatcat caaatagaac cgaatggaat cctcattgaa tggaaatgaa 60aggggtcatc atctaatgga atcgcatgga atcatcatca aatggaatcg aatggaatca 120tcatcaaatg gaatcgaatg gaatcatcat caaatggaat ctgatggaat cattgaacag 180aattgaatgg aatcgtcatc gaatgaattg aat 21325229DNAHomo sapiens 25gaattctgtg cgtattttag aagtagaatt ataagatttg tggatatgtt agttttggag 60tgtgaggtca aaggcgtttt gagcaacttg taagaaacca tttttaaggc ggaagtcggg 120aattttgttt tttatatgtt gaatttgaaa tccttattaa acatccaagt ggagaggctg 180gatagacaat taaatttaga ccctgaggtt cgggaaggaa gtccaatgg 22926216DNAHomo sapiens 26gaattcttca agaaacatca aggagggatg tatagatagt tttttaaaaa accgaaatgt 60aaaagaaata caagaagaat ggaaacatct acataacgag agtggaaaga aatgaaaata 120gaggtagata gattagatag atagatagat agatagattg attgatggat tgatagattg 180atagatatag aaataaaaga aagaaaatag aagatg 21627244DNAHomo sapiens 27gaattccaat gcaatgttaa acagaaagca gccctttttt tcaaaattta taggcaaggt 60gtttaacata tggctaaata atgttaattt atagtaaata tccttcataa ggatgaagat 120gtacccttct attttagttt gctgagtgtc ttttagtcat aattgagtgt tgacatctgt 180caaatatttt ttctgcatct attaagacat ccatgtgata tttctctttt attctcttac 240tatg 24428237DNAHomo sapiens 28gaattcaatc accatcgaat acaatcgaat ggagtcatcg aatcgactca agtggaataa 60tcattgaatg gaatcgaatg gaatcatcga gtggaatcga atggaatcat gatgaaatgg 120aatcgaatgt aatcatcatc aaatggaatc aaaaataaac atcatcaatt ggtattgaat 180ggaattgtca tcaaatggaa ttcctgcagc ccgggggatc cactagttct agagcgg 23729184DNAHomo sapiens 29gaattctttc cagaaggttt ttaatttact ttgctcggct ccatcagggg aatcactatg 60gcagctatag ccttaagaaa tttatttctt aaataagact tgagagtcag aattgcttct 120ttatccatgg tctcgaggat gggatgttgt gatagcaggc gtgaaaacaa cattcatctc 180ctgg 18430191DNAHomo sapiens 30gaattcagaa tctggatggc aaggaagcgc atcaagatgc aggagaaagt tgaaacctaa 60tccaaggaat acagtaaaac aatccagaag cttgaaagac aaaatagcca ttttaagaac 120caaactgagc ttctggaagg gaaaaattta cttcaagaat ttcataatac aatcaaaagt 180attttttttt t 19131143DNAHomo sapiensmodified_base(48)..(48)a, c, t or g 31gaattccgct tggggaggga actgtcttcg tccaggaaaa tgtttttnat aagccaccca 60tggtaaaagg agaagtcatg acggttaggg tgttggcagg aatcaaatta agaaaaggaa 120tggctatcca tccggttgta tgt 14332169DNAHomo sapiens 32gaattctaga ctgctgcacc tccatatcct cagcaactgg catgatgatg agcagggagt 60tagtagaact aatacactaa tatgtaaatg aatgaatgaa tgtttcctga gtgtggcttt 120aagtttctca gaagaagaca gttcatacac tggtgcataa aattctggg 16933124DNAHomo sapiens 33gaattctagg acaaggtgat tgtcctagat tttctcttaa acgcctcctg ttagatagga 60aatggccatt aatagagaag cttgcttgag ggagtaaccc tgaaagccca ggcctggaca 120cccg 12434214DNAHomo sapiens 34gaattctaag tttatatagg ttacaacatc acagtaagaa tgtcacagag gggtatatgc 60ttttcatcaa acaacaaatt gaaaattttt taactcttaa ggactgattt tgcttaacta 120caagttatgc actgatggta gtagcttcat aaatttagaa aagttccaaa ataatgctta 180gaaagagtag ctatttaact tctcattgaa caaa 21435164DNAHomo sapiens 35gaattcctgt gaatgtcgtt tcaaatatta ctcagcctac gcactgacca gaacttattt 60tttacagaat cattttgaca ggaaaagtgt ttatgatagt tttgttgttg ttgttgttgt 120tttgtttttt catcacccag gctgcttcac atttagagct gagt 16436119DNAHomo sapiensmodified_base(88)..(88)a, c, t or g 36gaattctgag aactagccct ttaagactgg tggagattta ttcaggaggg aagccctgcc 60ccagggaaaa gttgccaaga gacttgtntt taggagatca ccagcccaaa tttccatga 11937208DNAHomo sapiens 37gaattccctt catatttttg gtcaaagccc agtttttctg agtcggtggg ctaaatggga 60ttactctttc taatgaggca tccttgtgtg cttagaatca ctcttgactt tatcctgtcc 120ccctcgggtt cctaacttac caggatggag agcatttcct cattccatgt tgttgggagg 180ttggcccact gggtgacatc agcccagg 20838169DNAHomo sapiens 38gaattcctta acccttaatt agctttggtt tttgctcaat atcctgaagc tgggcacagt 60ctcaatgtaa ctattctcct aggggctgaa ctgggtgcta gtcatcaaag tttggaatgt 120cattttagaa gcaacctcta gaagtaatcc tggtaagccc tagaagtaa 16939172DNAHomo sapiens 39gaattcccat ctttttttgt gtgtgtgttt gagactgtat tttgcattgt cgtccacact 60ggagtacagt ggcgtgatct ccgctcgctg caagctccgc ctcatggatt taagcgattc 120tcctgcctca gcctcccaag tggctgggac tacaggtgcc cgaccaacca cg 17240137DNAHomo sapiensmodified_base(124)..(124)a, c, t or g 40gaattctgtt acttggtgat gggaaaccgt gaaggtttta agcaagactg tgatgtgctt 60aggtttatta gaaggttcta tgctgctcag cctccctgtc tagttctttg ctttattgac 120tgtntcctca ctaaatg 13741152DNAHomo sapiens 41gaattctttt ttccccagct ttatggagat ttaattgaca aataaaatgg catatattta 60ggtgtatata tttgatatat gtatacattg tgaaacgatt actataatga agttaattaa 120catattcctc atcttgcata gtcaccattt tt 15242183DNAHomo sapiens 42gaattctcca tgaaaacaga catatttgat atttaggtgc tttaatggac cctgaaaaga 60aattagattg attcatttga agaataaatg tcggtccccc gccctctaca tggtaaaact 120cttccaaatg cttctactta atggaaatgg aaattacctc tcaaaacatt acaaaaacta 180atg 18343162DNAHomo sapiensmodified_base(43)..(43)a, c, t or g 43gaattccgac cactgctgac cgccaggcca cacaccggtt ttnttcagga ggtctcaact 60agatgctaag ctccgaagtg gaactccctc aggcactttc tgttctaatt caggaattcc 120tcgagcccgg gggatccact agttctagag cggccgccac cg 16244189DNAHomo sapiens 44gaattctgtg aaataattct cagcccagac ccaagggatc cacagctcag aaataggtta 60tccagaagtg ttcctaacac tagatgacag tatcccagtg ctccaaacca gcttattact 120tggccagaat tcctgcagcc cgggggatcc actagttcta gagcggccgc caccgcggtg 180gagctccag 18945190DNAHomo sapiens 45gaattctctg tctgtcgatt tcagtgattt tagtgctggt cctccacttg agtactagcc 60ataggtcttg gcttggcact cccatcccat agccctgtgc accatagctc tggggtgaac 120tcaggcaaaa cgattttcgt ccccagcttg ggagcagcag ggttggggac cttggcaatg 180gcaatggcag 19046266DNAHomo sapiens 46gtaatacgac tcactatagg gcgaattggg taccgggccc cccctcgagg tcgacggtat 60cgataagctt gatatcggct tatcctgagc taggctgagc ctttgctctc ctgacctagt 120tagttctcat tcaaccctgt gacaagggat gtggggctca gagaacggga gggtcttccc 180tcaggtcaca tggccagggc atggagaggc aggacttgaa tccaggtcaa tgtgacccca 240gagcctagtg tggaaacccg tccttt 26647164DNAHomo sapiensmodified_base(81)..(81)a, c, t or g 47gaattctacc ctgggtagga tagtagctcc cctcaacttt acagcaaata cagctaacct 60tgctttacct gcgatcccgt ntttattttg ttgaattaga gaaactgagg gaagcagttc 120tctacactca ctttaccctt agagccctct acaatcaacc ctgt 16448112DNAHomo sapiensmodified_base(16)..(16)a, c, t or g 48gaattcaaag actgtnagat gtaagcagtg actganacan aggcaatgag atgagaggtg 60gaaaggagac caaatgtaaa agacagcaga aacttgagtg gacggtggca ca 11249114DNAHomo sapiensmodified_base(52)..(52)a, c, t or g 49gaattctgtt ggctttacct ttaacgtgtc caaaagtgac caattatcat tnctgcnttt 60ngctgctact tggntcaagc cattagtatc ccttgctcca ataaactctt tcct 11450206DNAHomo sapiens 50gaattcccag taacttcctt gtgttgtgtg tgttcaactc acagagttga actttcattt 60acacagagca gatttgaaac actctttttg tggaatttgc aaatggagaa ttcctgcagc 120ccgggggatc cactagttct agagcggccg ccaccgcggt ggagctccag cttttgttcc 180ctttagcgag ggttaattgc gcgctt 20651169DNAHomo sapiens 51ccccccctcg aggtcgacgg tatcgataag ctggatatcg gcaacttctc gctctgtcct 60cacataggga aagaggaagc tgttgccttc ctcttacaag agcactaatc tcacatgggt 120gtttaccctc atgactttat ctaaacctaa ttatctttca aagaatcta 16952141DNAHomo sapiens 52gaattcttgt tttcagtgaa aatttagata atttatctca ggaattcctg cagcccgggg 60tttccactag ttctagagcg gccgccaccg cggtggagct ccagcttttg ttccctttag 120ttagggttaa ttcgcgcttg c 14153203DNAHomo sapiens 53gaattctata tatttcccct cttttcctga ctcttcagtg acaatcctaa gaccgtgcta 60ataacagaag acagtaatcc ctttttttag ccaaataatt tggaagccat gattttcttt 120gcatatcatg aaagtgacca tggtgttgga tattgtgggt agaagctttc aagtaaaaaa 180gaactgtcat tcaactgaat tgg 20354162DNAHomo sapiens 54gaattctagg ccaggcgcga tggttcacac ctgtaatccc agcattttcc cgggaagcca 60aggcaggcag atcacttgag gccaagagtt caagaccaac ctggccaaag gggtgaaatc 120catctctact aaaaatacaa aaattagtcg ggcgcggcgg cg 16255193DNAHomo sapiens 55gaattctatt tctaggaacg ttctcaaaca agcttaagag caaagtataa aaacgatgtt 60cagcatataa taatatgaaa aaattttgtc ctagacattt tatatgaaaa tgtatacttt 120agagcatgct tcaggaaaaa aagaaagaaa aattaatcct gggaaatggg tgacattaga 180tacaggcgag tgg 19356169DNAHomo sapiens 56gaattctgct tttatgagaa gtcagctgaa tgctatggaa aggagtatag agagtggctt 60aaaagtttca ggcaagttca caccaaaact tgcattctaa cctccctgaa cctgtggtct 120agaagggacc tatcagcaag atgataacca aaaatgtcta gaatctgag 16957141DNAHomo sapiens 57gaattctaga gaacaatccc tactgacttc acacacaact taagaaatgc aagtaaaggg 60ccgggcgcgg tggcccagca cctgtaatcc cagtactttg ggagcctaga ggcaggtggt 120cattggaagt caggagttca a 14158183DNAHomo sapiens 58gaattctctg atgtttagtt aggtatgacc tacagttaaa ggctttgctg cattccttac 60gtttgtaggg tttctctccg gtatgactac ttcgatgtcg agtaacggac gttgaattac 120gataaaaggc tttgccacat tctttgcatt tatagggttt ttctccagta tgaattccag 180cag 18359185DNAHomo sapiens 59gaattctatc aatgtcaatt aaatccagtt gatggatggc cataatttta aatctattta 60cattttgggg tattttttaa aataaaatct gtgattatct atcttttaat gaatgcctta 120gatcattcac attaaagtga ttgttgttgt agttgtgttc atgtatacca tacttataac 180tgttt 18560163DNAHomo sapiens 60gaattctact aaaactttag aaaagaaatt aacaccaatt ctcaaactat ttcagaaaat 60tgaaaaggag aagcctctcc caactaattc tatgaatcca gcattacccc ttaccaaaac 120cagacaaaga tgaaacaaaa taataagaag aaggaactct

ggg 16361103DNAHomo sapiensmodified_base(63)..(63)a, c, t or g 61attttccctg ctgggtgtgt ccagagatcc tttctggcta gtctgctagc actgcatgtg 60tcnaccagca tctcaacctc acactagctg caacacttgg cca 10362144DNAHomo sapiensmodified_base(60)..(60)a, c, t or g 62cctctccaaa aagaaaatct ctgccattct atgtacactg gctgcatgaa gatgtatgtn 60tatgaattag cctgcatgtc tgggtcccac cctgcacatg ctaacattcc tttccctccc 120catacgagtc caaaaaaact atgc 14463173DNAHomo sapiens 63tcagtcttca ggtgatattg aaatggaggc tgtaaggttt taataataca ggtttcaaaa 60ccaggcagca acacatacta gccatgtaaa acttgagcta ccccaacccg cctggttgtt 120gcttagtcct tctttgaaaa ttaaaattct gttctctgga aatagtattt agg 17364150DNAHomo sapiens 64ttacaacctt tatgagattg gtgccattat caccattttc agacatgaaa aatacagcac 60acacagttta agtaatatgc tgaattcctg cagcccgggg gatccactag ttctagagcg 120gccgccaccg cggtggagct ccagcttttg 15065159DNAHomo sapiens 65ccagtaactt ccttgtgttg tgtacattca actcacagag ttgaacgttc ccttagacag 60agcagatttg aaacactctt tttgtgcaat tggcaagtgg agatttcaag cgctttaagg 120tcaatggcag aaaaggaaat atcttcgttt caaaactag 1596673DNAHomo sapiensmodified_base(26)..(26)a, c, t or g 66tcccaatcct tcctgtgact caagcntctg ctcattaggt atcctaggac aatattatgc 60tgtntctatc aga 736787DNAHomo sapiens 67agccagagcc aagctctctc actctgcaga gaagcctcag tctttagaag acagttcagc 60tttatccaga attcctgcag ccggggg 8768110DNAHomo sapiensmodified_base(104)..(104)a, c, t or g 68tatgatcaac aaatatatct tacaacatga gggtgcaata agatgagaaa ggttcgagag 60tgtttatctt tagcaaatac atactatcgc gctcaaggta agtnttcaag 11069111DNAHomo sapiensmodified_base(46)..(46)a, c, t or g 69tattgtgccc agagataatt gtcctgcagt cagagcattc tatgtntttn tctgtcgttg 60attaatcaag agggtttcag gcttccctgt aggaaaatgt ctaaagcata a 11170138DNAHomo sapiensmodified_base(80)..(80)a, c, t or g 70attcatttat accctcattt attcatccaa cagccattca ataagcgtct gtgttcagcc 60atgctctgac actgattgan ttcctgcagc cgggggatcc actagttcta gagcggccgc 120accgaggtgg acgtcagc 13871144DNAHomo sapiens 71caggttgatg aagaaacgga tattagtgca atgaagaaca gctccgtctc tgtcagctgg 60tcatttttta tatgtcagag actgtcgaat ttctattgcg tttcaactaa ttacctcagt 120ttgttaaaac tgaatatgaa ttcc 14472113DNAHomo sapiensmodified_base(1)..(1)a, c, t or g 72ntctatctag ttttatatga aganatcacg tatcacacga tggacccaaa gaggtccaaa 60tatccacttg cagttctaca aaaagagtgt ttcacaacag cactatcaag agg 1137397DNAHomo sapiens 73tacattcttt ttcttaacta tccaccacct cccctcaaaa ttttaacagc atccagcctc 60acaaaactca gatcttccct gtgtacagtt ccacttt 9774143DNAHomo sapiens 74gacaattcca ttcaatacca attgatgatg tttatttttg attccatttg atgatgatta 60cattcgattc catttcatca tgattccatt cgattccact cgatgattcc attcgattcc 120attcaatgat tattccactt gag 1437598DNAHomo sapiensmodified_base(30)..(30)a, c, t or g 75aaatgataat atagtcaatt caggaaagan aatcatccta anatttcgta ttatgattag 60aagtgtaatt tcgctganat agaaaatttc tcattatt 987688DNAHomo sapiens 76agctgacatt gtaatttaat aaagctaagg ataaaacttc tgggtttttt gtttattgag 60cccgctgact agaagagata agagatgg 8877101DNAHomo sapiensmodified_base(23)..(23)a, c, t or g 77ctctggttgt tgtcaggttt ttnattatta gattccagaa ttcctgcagc ccggnggatc 60cactagttct agagcggccg ccaccgcggt ggagctccag c 10178109DNAHomo sapiens 78aaggttacag tgagctatga tccaccactg cactccagca tgggcaacaa agcgagaccc 60agtatttaga tttatttgtt aatagccagg catattggta catgcgtgt 10979121DNAHomo sapiensmodified_base(61)..(61)a, c, t or g 79ctatatcaca tactttattg tcttgtacag tttgctttgt ttcatgtgtg gataccctga 60nttcctgcag cccgggggat ccactagttc tagagcggcc gccaccgcgg tggagctcca 120g 12180144DNAHomo sapiensmodified_base(106)..(106)a, c, t or g 80ctatgagtgg cctccaagga gcattagatt agaaggtggc tggagggtgg atattttcat 60acacagagac aaagctcccc atcccacaac agatccagag tctgtnttgg accacaggga 120aggaaggccc ttctccagga ttct 14481160DNAHomo sapiens 81ttaggagagg tcagagtggg ctggagcagc caggtgagcc tttgttgtgt aggcaggagg 60aagaagcagt ggattttgag ttgaggacgg aatttgagag ggggagggaa aaggaaggga 120atccgcagag gcagagctga ctgcactcgt gagggagggg 16082164DNAHomo sapiens 82atacaaattg cagactgcag cgttctgaga aacatctttg tgatgtttgt attcaggaca 60gagagttgaa cattccctat catagagcag gttggaatca ctccttttgt agtatctgga 120agtggacatt tggagcgctt tcaggcctat gttggaaaag gaaa 16483164DNAHomo sapiens 83ttgtggttct agattttatg gtctcttttt tatttttcat tttttgagac caagtttcac 60tcttgttgcc cggctggagt gcagtgacgc gatcttggct caccgcaacc tctgcctcca 120ggattcaagc gattcgcctg cctcagcctt actgagtagc tccc 16484141DNAHomo sapiensmodified_base(67)..(67)a, c, t or g 84tagttccagc tataccactt tctagccttc ttgattttgc tgaactgaga gtcagaagag 60atatgtntct aggttatttc caatcattat gccatctcgg aagtggcagg ggtgctatac 120tagactgaga caaatacccc a 1418572DNAHomo sapiensmodified_base(26)..(26)a, c, t or g 85cttctaaaat tctatggtag tatganaggc tacacaaaag tntttggacc tgatacaaat 60attataaatg at 7286135DNAHomo sapiens 86tcataaaata accattaata tttcactttc gttttttatc ctaacctttt tctaacacat 60aaacatattc attgggaggt cgaggcgggc ggatcacgag gtaggagatc gacgaccatc 120cggtaaaagg tgaaa 13587107DNAHomo sapiens 87cagccccaag aatgtctgga gcccgagtat catctggcag ccaccctcgg agaagggggg 60gatccactag ttctagagcg gccgcaccgc ggtggagctc agctttt 10788109DNAHomo sapiens 88ccatgtggaa gcacagctat aaggctcttt ctatgaacca gaaagcaggc tttctctaaa 60caccgaatct gccaatgcct tgatcttgga tttcccagat tccgaacta 10989112DNAHomo sapiens 89cagggactta atcaacgcaa gcttatgacc cgcacttact gggaattcct cgttcatggg 60gaataattgc aatccccgat ccccatcacg aatggggttc aacgggttac cc 11290125DNAHomo sapiens 90acctgtaatc ccaactactc tggaggctga ggcaggagaa tggcatgaac ccgggaggtg 60gaggatgcag tgagccaaga ttgtgccact gaactctagc ccaggcaaag gtgagagact 120tgatc 12591130DNAHomo sapiensmodified_base(20)..(20)a, c, t or g 91cacttaagat tgtatctttn actctatgag ttatttctca ataaaaagta aaattnannn 60tactaataat taganatnat cttctctaga atgagcattn aatgagtcag ctagagaggc 120gacttaactg 13092104DNAHomo sapiensmodified_base(81)..(81)a, c, t or g 92cagcccttac attgtgtctg tgacccagtg ttaaatgaga cccaggtcaa gagacaactc 60tttggctggt ctaggatatt ntataanata gatctatcac tctg 10493122DNAHomo sapiens 93cgtcagctca gcagcctgac aatttgaact cagtagtatc acattgccac atggctatgt 60tcaggggtta atacttctta gcaaagaaat agagaccaat ctctgtgatc actttaaact 120tt 1229476DNAHomo sapiensmodified_base(50)..(51)a, c, t or g 94cacatggatg gggaggcctt ccaatcatgg cagaaggcaa aggagaaagn nagcacatct 60tacaggcagc aggcaa 7695109DNAHomo sapiensmodified_base(24)..(24)a, c, t or g 95cagccccagc atggcaggaa tatntntngc attgggttct ttggaggagg aaagtacgtn 60ctcagagnag gcaatttntc gccgctggtt taaggctttn natgaccga 10996148DNAHomo sapiensmodified_base(22)..(22)a, c, t or g 96cagccccgaa ttatgtatta anagttatcc tcaccaagaa agacaaggtt tctgtagttc 60tctaacatca tatccctata tanntntnac tgtgcagtat ccagacaatg acactccttc 120agagagaatt ctatggccac atctctaa 14897122DNAHomo sapiensmodified_base(41)..(42)a, c, t or g 97taaaactttg ttataagaga tggaagggtt taaatatata nntctaannn nttntagttt 60aaagaattcc aaacttaaac atcttcagta gacttgacat tgtatttcgn atatcctatg 120tc 1229888DNAHomo sapiensmodified_base(38)..(46)a, c, t or g 98ctttaaattt ataaactcca aggcagtaca agtctggnnn nnnnnnagct acccaatatc 60tgataaatat gaatacctaa taatagac 8899105DNAHomo sapiens 99tcctaaaact ctccctcacc agcatcccaa tttaaagcct tggtccttgc tcctccctct 60agggggatcc actagttcta gagcggccgc caccgcggtg gagct 10510086DNAHomo sapiensmodified_base(22)..(25)a, c, t or g 100cgccactatg ctcagctact tnnnntntgt tttgtagaga tgggtgtttc accatgttgc 60ccagactgat cttnanctcc tgggtc 86101156DNAHomo sapiensmodified_base(17)..(17)a, c, t or g 101gaccctccac tgatttncca tcttgaccac tgcctaccca attactgtnc cagtcgaaac 60ctgggcgcca tgtgacgact ctctccctct ctacagctac acaaccgccg tgtgctgtcg 120ggtcttatcc tttccaccca gtccatggct tggtct 156102173DNAHomo sapiensmodified_base(41)..(41)a, c, t or g 102cagccccata aaattaacca tcacactagg tgatgtcttt nttttttgag agcaagtctt 60gctcgtcacc aggctggaat actgtggtgg gatctcagct cactgcacct ccacctcctg 120ggttccagca attgttctgc ctcagcctgg gggatccact agttctagag cgg 173103191DNAHomo sapiens 103cagccccctt agaaatagct cttcgagaca ctcctggtag acatgatccc aggcttgctg 60agcagctgtg caaccatgcc tcaggcctga ggaacagctc gcaggccact ctgtctggta 120ataccccagg ccggccaagc aatagatctg catcccaggg ggatccacta gttctagagc 180ggccgccacc g 191104191DNAHomo sapiensmodified_base(74)..(74)a, c, t or g 104gagccccctt ggctcagtct ggaaaggcaa gacaactaga aggtgggggg cttccagggc 60ataggtagat tcanaaatgt actgattggc acttccttga ccgagttatt aactaaagac 120ctggaatcaa tagaaaggaa tgtctgggtt aaggtaaggg ctatggggga tccactagtt 180ctagacggcc g 191105103DNAHomo sapiensmodified_base(5)..(5)a, c, t or g 105ttctnagana tttnacatca nattaaccca ctganaaact tgcnaactct cactttcaac 60gtctgancgg naattttaat tggnggatcc actagttcta gag 103106120DNAHomo sapiensmodified_base(44)..(44)a, c, t or g 106cagccccctt attaactcac cccttgcatt tgttcaaccc tagntaataa agtcactcag 60gtgtacttct ganaattgaa gttaaatatt tttcaccaca gagctgaacc attacagagg 120107111DNAHomo sapiensmodified_base(7)..(7)a, c, t or g 107tcataanata accattaata tnnnnntnnn nnnnnnatcc taacattttt ctaacacata 60aacatattca cttgggaggc cgaggcgggc ggatcacgag gtcaggagat c 11110870DNAHomo sapiensmodified_base(26)..(26)a, c, t or g 108caatttacac tctggcaggg ggaganagga naatttntnc tgtnggaagg gggagttgng 60gnaggaggcc 70109104DNAHomo sapiensmodified_base(5)..(5)a, c, t or g 109caaanactaa natacctctn agtctggnta gacactttca ctggataggt agaggccttt 60nctacaggnt atnanaaggc caccacagtc atttnttccc ttct 10411068DNAHomo sapiensmodified_base(13)..(13)a, c, t or g 110tcatgtaggc ctnttcacga ttttnnaaat catttnagtn acatccaagt nnnnntngct 60gttaatca 68111107DNAHomo sapiensmodified_base(43)..(44)a, c, t or g 111cagccccaat caagggctgt ttctcaatct ctttgtataa aannctagat tctgtattag 60tctgttctca ggctgctaat aaagacatac ccaaggctgc gtacttt 107112111DNAHomo sapiens 112tggaaagaaa aactatgtac atctgagacg ctgcagctgg tatcctactt ctttcagagc 60atcaacaggt taagtgtgga ttcatccaca ccctcagacc cgtgaccgta g 111113121DNAHomo sapiens 113gaatctctac accaaccctc tcttaacctc tacagttcaa atccaaatct caaactttct 60gatttgaatt tgcttatccc tatgtaattc taacttaaga cctaagacca aaagggaatc 120c 121114103DNAHomo sapiensmodified_base(60)..(60)a, c, t or g 114tcttccagct aaatagttgc agagtcagag tagaagccag ctctcctgac aatatatttn 60atgatattct agagaatatc cctagaatca ttcctaggta ctc 10311586DNAHomo sapiensmodified_base(41)..(41)a, c, t or g 115tgtcattggt aatttatgtg agaacacaaa gcatccaaca ntanntgatt ctgcatttcg 60accaacagat agtttctcat cgaaga 86116120DNAHomo sapiensmodified_base(23)..(23)a, c, t or g 116cagccccgtt tgttttacct ttngcttttn atgtgcttct ctaacanttn agggcgaact 60aaccagcatg aggnttgtnt ctgcttgatt ttnaaccatc ctttcctgtc tgtacacagg 12011795DNAHomo sapiensmodified_base(15)..(15)a, c, t or g 117ccctccctga gtctntntaa cagcagcact gcccccaaac ctnanttggt tcccctgata 60gccaggtacc cggnttctnt ngcagtgcta actgt 95118109DNAHomo sapiensmodified_base(7)..(11)a, c, t or g 118tattaannnn nctaatctna atattntngt ntctcgggga acagaaaagc ctgaggagaa 60ggagagatag tnggaatntc tagttnttgg agcagtcaga acacacata 10911979DNAHomo sapiensmodified_base(68)..(73)a, c, t or g 119cctgtattac agaaccaagg attaaaaact cagcagatgt gtaatgagtt ttaaataatt 60acaatatnnn nnntataaa 7912083DNAHomo sapiensmodified_base(12)..(13)a, c, t or g 120tagttgatcc gnnagcccat gcgataccgc gnnggcgctc gnngccgang ggggatccac 60tagttctaga gcggccgcca ccg 83121177DNAHomo sapiens 121cgtttgtttt acctttcact tttaatgtgc tttctctaac aattaagggc gaactaacca 60gcatgaggat tgtgtctgct tgattttaaa ccatccttta atgtctgtac acaggaaatg 120ttatcaacaa gagatgattc ttgggggatc cactaggttc tagagcggcc gccaccg 177122103DNAHomo sapiensmodified_base(12)..(12)a, c, t or g 122ttatagttta anacanagat ggtaacagcc ctttcccaaa gcagacctcc ttcttgcctg 60gnaaagggct gttaccatct ttgttttaaa ctataaacta taa 103123139DNAHomo sapiensmodified_base(24)..(24)a, c, t or g 123caagaagggt ggtgctggca tttncttctg gtgagggcct caggaagctt tcaatcatgg 60cagaaagtga gaggagagta ggcatgtcac anagagagac atgccttcat tctcggggga 120tccactagtt ctagagcgg 139124103DNAHomo sapiensmodified_base(14)..(14)a, c, t or g 124cattaaagcc tttnttagga aatctnttta aacaacagaa taaaagggat gactttnaga 60tagaactttn ngtgacatct ccagtttctg gttacatgat att 103125103DNAHomo sapiensmodified_base(17)..(17)a, c, t or g 125cagagagaga gaaacanaca gncagagaga gagagaccac anagagagag agagagagaa 60gatcagacag agaaaganag agacagagac agacannnag aca 103126113DNAHomo sapiensmodified_base(29)..(29)a, c, t or g 126cagccccaga gagagagaaa cagacaggna gagagagaga gacacagaga gagagagaga 60gagaagatca gacagagaaa gagagagaca gagacagaca nanagaatag aga 113127181DNAHomo sapiens 127actcatttta tgaggccaga atcatcctga taccaaaacc tggcagagac acacacacac 60aaaagaaaat ttcaggccaa tatccctgat aaacattgat gcaaaaatcc tcaataaaat 120actggcaaac tgaatccagt agcacatcaa aaagctgggg gatccactag ttctagagcg 180g 181128150DNAHomo sapiens 128cccgccccat gtagctctca ggtggcccat gacaccacac tgttcttcct tcctctccat 60gggtcacacc ggccacctag tcagtcctaa cgtcggaacc tggatacctc cattgctggt 120gctggacccg tcactgtttt ggatattttc 150129173DNAHomo sapiens 129tcctaagtgt cccaacagtg gagcacatta ttcaggaact taaagatata atcgcagaac 60agcacctcca agctcgtaaa tgcttatctc ggtaaccctc agtcatggga caatcaaatt 120caatacatcg gaggaacacc atgctgacgg gggatccact agttctagag cgg 173130187DNAHomo sapiensmodified_base(23)..(24)a, c, t or g 130ctatagaagc tccttctata ttnngcttat nncactcatg gcggtagttt gaattcagat 60ctctgggtca tttattatcc atggaaagtt aatttgagat gttggaactt ttaaacagtg 120tttgtttatt gtgctaatca cgatctgtta ctaaatttga ttgggggatc cactagttct 180agagcgg 187131170DNAHomo sapiens 131cagatatttg tagatatgcc gcgttatttc tgagggctct gttctgttcc attgatctat 60atctctgtct ttggtaccag taccatgctg ttttggttac tgtagccttg tagtatagtt 120tgaagtcagg tagcatgatg cctccggggg atccactagt tctagagcgg 170132147DNAHomo sapiensmodified_base(69)..(79)a, c, t or g 132tctctaaaat tctatggtag ttgaaaggct acacaaaagt ttttggacct gatacaaata 60ttataaatnn nnnnnnnnnt gtntgatttg atactccatg taaaactctt cctaatggtc 120tcgggggatc cactagttct agagcgg 147133123DNAHomo sapiens 133tattaaaaat acaaaaaatt agccgggagt ggtggcacgc gcctgtagtc ccagctactc 60gggaggctat ggcaggaaaa tcccttgaac ctgggaggcg gaagttgcag cgagaagaga 120tca 123134164DNAHomo sapiens 134ctgtctttca agtttcaggc ttgaaagtga aaaataatgc ataatttacg gaagctattg 60gtgtgaaaat atccaagaga agaatgagga atagtggagt gaaataaaca ggagattagg 120tagatagaaa ttgactattg ggggatccac tagttctaga gcgg 164135193DNAHomo sapiensmodified_base(60)..(60)a, c, t or g 135cttaatatgg tatgcttaat gtagtgagct aaacaaaata acaatgtgta tagtattgtn 60taanataccc cacttccaat tgtttaaagt gcaaaacaaa ttatatgttt ganagttaag 120gtggaataaa tgaagattaa atgatatgaa ctactcagaa aacaggtagg gggatccact 180agttctagag cgg 193136233DNAHomo sapiens 136cattgattaa atttattgat gcattgtaaa tttgaatcaa tatctattaa tcccaagctg 60gagtgcagtg gcgccatctc agctcactgc gacctctgcc tcccgggttc aagcaattct 120catacctcag cctcccgagt agctggaacc acaggcatga gccaccatgc ccggctagtt 180acagggtttt cctatgctat ccaggctgga gtgcagtggg ggatccacta gtt 233137194DNAHomo sapiens 137ctaaaggatc cttcaactct gtgagttgaa tacacacaac acaaggaagt tactgagaat 60tattctgtct agcataatat gaagaaatcc cgtttccaac tgaagacctc aaagaggctg 120aatatccact tgcagacttt acagagtgtt tcctaactgc tctatgagag ggggatccac 180tagttctaga gcgg 194138155DNAHomo sapiens 138cagcccggaa aatatagggc

aaattttttt attttgctgt ttggtgactc caccactttt 60gcaacagtac ttttggtgcc cattaaccaa attactttga tttctttgtg taaatattat 120gaagaccaga accttttgag ggggatccac tagtt 155139200DNAHomo sapiens 139ctagacaaaa gccccatcac ctggatgaat cagtgcagag ttacgtcaca aagtcctttt 60aggcagatcc tagacaaggg ttacatcact tggatgatca gtgcagagat atgtcacaat 120gccactgtag ggtgagccta gaaaagagtt tcatgaccta ggtgatcagt gcagaggggg 180atccactagt tctagagcgg 200140169DNAHomo sapiens 140ctgtgactgt gcctatagaa gaaaaaaaaa atagcgtgta atctcagcac tctgggaggc 60caaagcaggg gggatcactt gaggccaaga gttcaagacc agcctggcca acaaagcgaa 120accttctctc tactaaaaat acaaaaatta gccgggcatg gtggcactc 169141211DNAHomo sapiens 141agggccacca gctggtgaat cctgccccac cagctcagag ctcttcccat tcatggagta 60tatcatagga gactggattt ccaaagctgc atggagcttc attcctgaac tggtcaccct 120gtgtctagtc ttgttttctc aatccatcct gctctccagc agcctcaata cttctaaaat 180tgtccggggg atccactagt tctagaggcg g 211142195DNAHomo sapiens 142cacagacatc ctgtgccacc tcattcactc tcacatgcct ctgaggtgag ggggataaca 60gcactagtat catttgatac tgatacaaat cggctctaaa tattgtgggg atgctggtgg 120tgttattgct ggactccatt acacaagttt catgagccag tgaaaatcac tgtgggggat 180ccactagttc tagag 195143199DNAHomo sapiens 143cagccctaaa gtataataaa aaaaaatttt ttaaagaatc ttcacaaaag aactctgaaa 60tgtcagcatg agcagatgat gaagtatcat aggaatccat tttttgctgt atttcttatt 120taatagagaa agaaatttca tatgctgtaa tatgtttcca attggaaatt aaaatctgat 180aggggggatc cactagttc 199144178DNAHomo sapiens 144cagcccccct gtaacaatat gggctgttct agctgtaatt cacctctgga gccatcagaa 60tcctcctggt aaaaatggcc ctaatatcaa acacagaggc cactgctagt taaactttat 120aaatcgaaca agaaatcata tgatataatc agataagagc ctgggggatc cactagtt 178145158DNAHomo sapiensmodified_base(68)..(68)a, c, t or g 145cagccccctg ggctcaagca atctgcccac ctcggcctcc ccaagtgctg ggattacagg 60tgtgagtnac tgtncccggc cagccttgtc tatttgtcag aaacagggag ttggggcaac 120cctggtgcca agatatgggg gggatccact agttctag 158146184DNAHomo sapiens 146cagcccctgc taaataactt tcgaagttaa gaaagctaat ggtatatcat caggcaccaa 60taaaactatc ttgagatttg acaatgccaa ctgaaaaatt tcttctgcaa ggcagagcca 120gttacctttt ataatatcaa tttagattca cacaaagaca ttctcagggg gatccactag 180ttct 184147219DNAHomo sapiensmodified_base(21)..(21)a, c, t or g 147cagccccacg ggtggtaatc ntggctgctt tntgcacttc cacataaagt gcttctncta 60cgctgtctcc actcagaaac aattacaaca gtatgtgaag cagtattgaa aacttcnnaa 120gctgcacaca gattcattga aaagggcaga agcctcatta atactagagt ctgaggcaca 180acctatgacc gaacactggg ggggatccac tagttctag 219148185DNAHomo sapiens 148cagcccccag aaaaaaaaga gcaagaggat ggggctgaaa aaattactca aagaaataat 60ggctaaaaag tactcaggtt tatcaaaaga caagtctgca gaactaagaa gatgacaaaa 120tccttgtcat agacagaatg tgtgtttccc aaacttcgtg tgttgggggg atccactagt 180tctag 185149129DNAHomo sapiens 149cagccctgca gtatttagtt ttctattcct gagttagttc acttaggaaa atggtctcta 60gctccatcca tgaagcacca aatccctcca gcccagtagc aaggagacag aatttttact 120ctgtctctg 12915074DNAHomo sapiensmodified_base(50)..(53)a, c, t or g 150cagcccctct tttctgctcc taaggaagat gcattctcag gatacaggan nnngggggga 60tccactagtt catg 7415195DNAHomo sapiens 151cagccccatt taacctggag aggaataccc taaggattct tggaggctga aagacttaaa 60atttgaggaa tgaaagaata gcaagggtga atcgg 95152144DNAHomo sapiens 152cagccctgca gtatttagtt ttctattcct gagttagttc acttaggaaa atggtctcta 60gctccatcca tgaagcacca aatccctcca gcccagtagc aaggagacag aatttttact 120ctgtctctga tgagaagagt gtac 144153138DNAHomo sapiens 153cagccctgat agttacctta ctgttttgct atgaccatac tctacataga gtatttagat 60taaatggagg aatgagaata tgagattagt ttctcatatt cttgtgatca tgacaggacc 120tgagattctg cacagatg 138154139DNAHomo sapiens 154cagccccgct gtttctaaag tcagtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgagag 60agagagagag agagagagcg tatgcatgtg tgtctgcatg tgtgtgtgcg cgcgtacatt 120tgggagacgg tgtgtaagt 139155133DNAHomo sapiens 155cagcccggaa aggtaataca agtaagatga ttataaacaa atgctttaaa acagagtcaa 60tgaaaccagt ctgtttgtga ggcccaaggc tccatatttt acaactcagt ctgtaaggat 120agctatgtat ctg 133

Claims

1. A method for suppressing spread of mutated DNA sequences within the body and development of somatic mosaicism in a subject in need thereof, wherein said method comprises administering a DNase enzyme to said subject, wherein said DNase enzyme is administered in a dose and regimen which is sufficient to decrease the average molecular weight of extracellular blood DNA in the blood of said subject.

2-4. (canceled)

5. The method according to claim 1, wherein said DNase enzyme is administered in a dose and regimen that results in a DNA hydrolytic activity measured in blood plasma that exceeds 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.

6. The method of claim 1, wherein the subject has a cancer and the development of somatic mosaicism results from a spread of mutated DNA sequences promoting cancer development.

7. The method of claim 6, wherein the subject has a metastatic cancer and the development of somatic mosaicism results from a spread of mutated DNA sequences promoting metastasis development.

8. The method of claim 1, wherein the subject has a cancer and is receiving a chemotherapy and the development of somatic mosaicism results from a spread of mutated DNA sequences promoting resistance to said cancer chemotherapy.

Images